

Table 1. Proportion of Medicare Parts A, B, and D Beneficiaries With Hypertension, With Use of One or More Antihypertensive Drugs, With Hypertension and Use of One or More Antihypertensive Drugs, and Average Number of Antihypertensive Drug Classes Prescribed, 2006-2009

Note: Age is calculated as of December 31 of the year.

			Number of Beneficiaries Enrolled in Medicare Parts A, B, and D	Number and Proportion of Beneficiaries Enrolled in Medicare Parts A, B, and D With Hypertension Diagnosis		Number and Proportion of Beneficiaries Enrolled in Medicare Parts A, B, and D With Any Antihypertensive Medication Use		Number and Proportion of Beneficiaries Enrolled in Medicare Parts A, B, and D With Hypertension Diagnosis and With Any Antihypertensive Medication Use		Average Number of Antihypertensive Medication Classes Used Among Beneficiaries With Enrollment in Medicare Parts A, B, and D and With Hypertension Diagnosis	
Breakdown	Category	Year	Number (in 100,000s)	Number (in 100,000s)	Proportion	Number (in 100,000s)	Proportion	Number (in 100,000s)	Proportion	Average Number	Standard Deviation
Total	All	2006	93.9	63.6	67.7%	64.3	68.4%	56.2	88.4%	2.0	1.3
Age	Under 65	2006	25.2	12.0	47.5%	12.2	48.2%	9.9	83.0%	1.8	1.3
	65 to 74	2006	29.5	21.2	71.8%	21.3	72.1%	18.9	89.4%	2.0	1.3
	75 to 84	2006	25.5	19.9	77.9%	20.0	78.2%	17.9	90.1%	2.0	1.3
	85 and over	2006	13.6	10.5	77.2%	10.9	79.7%	9.4	89.3%	2.0	1.2
Gender	Male	2006	35.4	22.0	62.1%	22.1	62.5%	18.9	86.0%	1.9	1.3
	Female	2006	58.5	41.6	71.1%	42.1	72.1%	37.3	89.7%	2.0	1.3
Race	White	2006	73.1	48.7	66.6%	50.0	68.4%	43.1	88.5%	1.9	1.2
	Black	2006	12.8	9.4	73.5%	9.0	70.3%	8.3	88.8%	2.2	1.4
	Other	2006	1.2	0.8	67.1%	0.8	65.4%	0.7	87.1%	1.9	1.3
	Asian	2006	2.6	1.9	73.6%	1.9	70.7%	1.7	88.5%	1.9	1.3
	Hispanic	2006	3.5	2.4	67.9%	2.3	64.0%	2.1	86.0%	1.9	1.3
	American Indian/Alaska Native	2006	0.6	0.4	58.4%	0.3	56.4%	0.3	82.0%	1.8	1.3
Comorbid Condition	Diabetes	2006	30.8	26.3	85.4%	26.1	84.8%	23.9	91.0%	2.2	1.3
	Cancer	2006	16.4	12.3	75.3%	12.3	75.4%	10.9	88.8%	2.0	1.3
	Osteoporosis	2006	12.6	9.7	77.0%	9.3	74.0%	8.5	87.8%	1.9	1.3
	Osteoarthritis	2006	31.0	25.1	80.7%	24.5	78.8%	22.4	89.5%	2.0	1.3
	Hyperlipidemia	2006	50.6	41.4	81.9%	40.2	79.6%	37.3	90.1%	2.1	1.3
	Cardiovascular disease	2006	39.2	33.2	84.6%	33.5	85.5%	30.2	91.1%	2.2	1.3
Total	All	2007	160.9	103.9	64.5%	103.9	64.6%	91.3	87.9%	1.9	1.3
Age	Under 65	2007	34.7	16.7	47.9%	16.7	48.2%	13.8	82.9%	1.8	1.3
	65 to 74	2007	54.3	36.3	66.8%	36.0	66.4%	31.9	88.1%	1.9	1.2
	75 to 84	2007	45.9	33.4	72.8%	33.2	72.4%	29.8	89.3%	2.0	1.3
	85 and over	2007	26.0	17.6	67.5%	17.9	68.9%	15.7	89.4%	2.0	1.2
Gender	Male	2007	61.9	37.2	60.0%	36.9	59.7%	31.8	85.5%	1.9	1.3
	Female	2007	99.0	66.7	67.4%	67.0	67.6%	59.5	89.2%	2.0	1.3
Race	White	2007	131.9	84.0	63.7%	85.0	64.5%	73.9	88.0%	1.9	1.2
	Black	2007	18.1	12.6	69.7%	12.0	66.4%	11.1	88.4%	2.2	1.4
	Other	2007	2.1	1.4	64.5%	1.3	61.7%	1.2	85.5%	1.8	1.3
	Asian	2007	3.4	2.4	70.8%	2.3	67.7%	2.1	87.8%	1.9	1.3

			Number of Beneficiaries Enrolled in Medicare Parts A, B, and D	Number and Proportion of Beneficiaries Enrolled in Medicare Parts A, B, and D With Hypertension Diagnosis		Number and Proportion of Beneficiaries Enrolled in Medicare Parts A, B, and D With Any Antihypertensive Medication Use		Number and Proportion of Beneficiaries Enrolled in Medicare Parts A, B, and D With Hypertension Diagnosis and With Any Antihypertensive Medication Use		Average Number of Antihypertensive Medication Classes Used Among Beneficiaries With Enrollment in Medicare Parts A, B, and D and With Hypertension Diagnosis	
Breakdown	Category	Year	Number (in 100,000s)	Number (in 100,000s)	Proportion	Number (in 100,000s)	Proportion	Number (in 100,000s)	Proportion	Average Number	Standard Deviation
	Hispanic	2007	4.6	3.0	64.3%	2.8	60.5%	2.5	85.8%	1.9	1.3
	American Indian/Alaska Native	2007	0.9	0.5	58.0%	0.5	55.9%	0.4	82.6%	1.8	1.3
Comorbid Condition	Diabetes	2007	47.4	40.8	86.0%	40.1	84.4%	36.9	90.5%	2.2	1.3
	Cancer	2007	29.4	21.9	74.5%	21.7	73.7%	19.2	88.0%	1.9	1.3
	Osteoporosis	2007	20.6	15.8	76.5%	15.0	72.8%	13.7	87.2%	1.9	1.3
	Osteoarthritis	2007	48.8	39.2	80.4%	37.9	77.7%	34.9	88.9%	2.0	1.3
	Hyperlipidemia	2007	86.4	70.8	82.0%	68.0	78.7%	63.2	89.2%	2.0	1.3
	Cardiovascular disease	2007	60.9	51.8	85.0%	52.0	85.3%	47.0	90.8%	2.2	1.3
Total	All	2008	172.7	107.5	62.3%	106.9	61.9%	94.6	88.0%	1.9	1.3
Age	Under 65	2008	36.1	17.3	47.9%	17.3	47.8%	14.4	83.0%	1.8	1.3
	65 to 74	2008	57.3	37.9	66.2%	37.5	65.4%	33.4	88.1%	1.9	1.2
	75 to 84	2008	48.3	33.9	70.1%	33.6	69.4%	30.4	89.6%	2.0	1.3
	85 and over	2008	31.0	18.5	59.5%	18.7	60.2%	16.6	89.7%	2.0	1.2
Gender	Male	2008	67.0	39.1	58.4%	38.6	57.7%	33.6	85.8%	1.9	1.3
	Female	2008	105.7	68.4	64.7%	68.3	64.6%	61.1	89.3%	2.0	1.3
Race	White	2008	141.9	87.3	61.5%	87.7	61.8%	76.9	88.0%	1.9	1.2
	Black	2008	19.0	12.7	66.7%	12.1	63.5%	11.3	88.8%	2.2	1.4
	Other	2008	2.3	1.5	63.1%	1.4	60.4%	1.3	85.8%	1.8	1.3
	Asian	2008	3.7	2.6	69.2%	2.5	66.1%	2.3	88.0%	1.9	1.3
	Hispanic	2008	4.8	3.0	61.9%	2.8	58.1%	2.5	85.9%	1.9	1.3
	American Indian/Alaska Native	2008	1.0	0.5	56.2%	0.5	54.7%	0.5	84.1%	1.9	1.3
Comorbid Condition	Diabetes	2008	49.4	42.9	86.8%	41.9	84.8%	38.9	90.6%	2.2	1.3
	Cancer	2008	30.8	23.3	75.6%	22.9	74.3%	20.5	88.2%	1.9	1.3
	Osteoporosis	2008	21.8	16.9	77.4%	16.0	73.4%	14.7	87.4%	1.9	1.3
	Osteoarthritis	2008	50.3	40.9	81.4%	39.4	78.3%	36.5	89.1%	2.0	1.3
	Hyperlipidemia	2008	91.0	75.2	82.7%	71.9	79.0%	67.2	89.4%	2.0	1.3
	Cardiovascular disease	2008	62.2	53.6	86.1%	53.3	85.7%	48.7	91.0%	2.2	1.3
Total	All	2009	183.7	110.4	60.1%	108.2	58.9%	96.5	87.4%	1.9	1.3
Age	Under 65	2009	37.7	18.1	48.1%	17.8	47.3%	15.0	82.5%	1.8	1.3
	65 to 74	2009	59.6	39.2	65.7%	38.0	63.8%	34.1	87.1%	1.8	1.3
	75 to 84	2009	50.4	34.1	67.8%	33.4	66.3%	30.4	89.2%	2.0	1.3

			Number of Beneficiaries Enrolled in Medicare Parts A, B, and D	Number and Proportion of Beneficiaries Enrolled in Medicare Parts A, B, and D With Hypertension Diagnosis		Number and Proportion of Beneficiaries Enrolled in Medicare Parts A, B, and D With Any Antihypertensive Medication Use		Number and Proportion of Beneficiaries Enrolled in Medicare Parts A, B, and D With Hypertension Diagnosis and With Any Antihypertensive Medication Use		Average Number of Antihypertensive Medication Classes Used Among Beneficiaries With Enrollment in Medicare Parts A, B, and D and With Hypertension Diagnosis	
Breakdown	Category	Year	Number (in 100,000s)	Number (in 100,000s)	Proportion	Number (in 100,000s)	Proportion	Number (in 100,000s)	Proportion	Average Number	Standard Deviation
	85 and over	2009	36.1	19.0	52.7%	19.0	52.7%	17.0	89.6%	2.0	1.2
Gender	Male	2009	71.8	40.8	56.8%	39.7	55.3%	34.8	85.3%	1.8	1.3
	Female	2009	111.9	69.6	62.2%	68.5	61.3%	61.7	88.7%	1.9	1.3
Race	White	2009	150.6	89.3	59.3%	88.3	58.6%	78.0	87.3%	1.9	1.2
	Black	2009	20.4	13.1	64.4%	12.4	60.9%	11.7	88.7%	2.2	1.4
	Other	2009	2.5	1.6	62.1%	1.5	59.2%	1.3	85.8%	1.8	1.3
	Asian	2009	4.0	2.7	67.5%	2.6	64.3%	2.4	88.0%	1.9	1.3
	Hispanic	2009	5.2	3.1	60.2%	2.9	56.2%	2.7	85.8%	1.9	1.3
	American Indian/Alaska Native	2009	1.0	0.6	54.7%	0.6	53.2%	0.5	84.6%	1.9	1.3
Comorbid Condition	Diabetes	2009	51.1	44.7	87.6%	43.2	84.5%	40.3	90.1%	2.2	1.3
	Cancer	2009	31.8	24.3	76.4%	23.6	74.2%	21.3	87.7%	1.9	1.3
	Osteoporosis	2009	22.4	17.5	78.2%	16.4	73.3%	15.2	87.0%	1.9	1.3
	Osteoarthritis	2009	51.6	42.4	82.1%	40.4	78.2%	37.6	88.7%	2.0	1.3
	Hyperlipidemia	2009	94.9	79.0	83.2%	74.7	78.7%	70.1	88.7%	2.0	1.3
	Cardiovascular disease	2009	62.9	54.8	87.1%	53.9	85.7%	49.7	90.8%	2.2	1.3

Table 2. Proportion of Medicare Parts A, B, and D Beneficiaries With Hypertension and Use of One or More Antihypertensive Drugs, by Drug Class, 2006-2009

Note: Age is calculated as of December 31 of the year. An asterisk (*) indicates a small cell count (<11).

Breakdown	Category	Year	Antihypertensive Medication Utilization (in 100,000s)																	
			ACE Inhibitors		Angiotensin II Receptor Antagonists		Calcium Channel Blockers		Diuretics		Beta-Blockers		Anti-Adrenergic Agents		Vasodilators		Other Renin-Angiotensin System Antagonists		Combined Therapy	
			No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Total	All	2006	21.3	33.5	9.7	15.2	19.2	30.3	25.1	39.4	26.6	41.8	5.8	9.0	1.2	1.9	0.1	0.1	15.8	24.8
Age*	Under 65	2006	4.2	34.7	1.5	12.1	3.0	25.0	4.2	35.1	4.5	37.7	1.2	9.8	0.3	2.7	0.0	0.1	2.5	20.7
	65 to 74	2006	7.3	34.3	3.4	15.8	6.2	29.2	7.6	35.7	8.8	41.7	1.9	8.8	0.3	1.5	0.0	0.1	6.1	28.9
	75 to 84	2006	6.5	32.8	3.3	16.8	6.5	32.8	8.1	40.7	8.8	44.1	1.8	9.3	0.3	1.7	0.0	0.1	5.2	26.1
	85 and over	2006	3.3	31.6	1.6	14.7	3.5	33.5	5.2	49.2	4.5	42.5	0.9	8.2	0.2	1.8	0.0	0.1	2.0	18.8
Gender	Male	2006	8.0	36.5	2.9	13.1	5.9	26.7	7.5	33.9	9.3	42.3	2.8	12.7	0.5	2.1	0.0	0.2	4.6	20.7
	Female	2006	13.2	31.8	6.8	16.4	13.4	32.1	17.6	42.3	17.3	41.6	3.0	7.1	0.7	1.7	0.0	0.1	11.2	27.0
Race	White	2006	16.4	33.7	7.2	14.7	13.7	28.2	19.4	39.8	20.8	42.7	4.0	8.1	0.7	1.3	0.1	0.1	11.7	24.1
	Black	2006	3.2	33.8	1.4	14.6	3.7	39.1	4.1	43.5	3.7	38.9	1.3	13.8	0.4	4.7	0.0	0.1	2.7	28.8
	Other	2006	0.3	31.0	0.2	20.4	0.3	33.5	0.2	29.0	0.3	41.2	0.1	9.0	0.0	1.7	0.0	0.1	0.2	25.0
	Asian	2006	0.5	23.5	0.5	27.0	0.8	38.9	0.4	22.9	0.8	38.9	0.2	9.1	0.0	1.3	0.0	0.1	0.5	26.5
	Hispanic	2006	0.9	35.6	0.4	18.2	0.7	30.0	0.8	32.6	0.9	38.1	0.2	8.5	0.0	1.7	0.0	0.1	0.6	24.4
	American Indian/ Alaska Native	2006	0.2	43.7	0.0	12.3	0.1	25.6	0.1	37.8	0.1	36.6	0.0	9.0	0.0	1.6	*	*	0.0	12.4
Comorbid Condition	Diabetes	2006	10.8	41.2	4.8	18.4	8.4	32.0	12.0	45.7	11.9	45.1	2.8	10.8	0.7	2.7	0.0	0.1	6.4	24.4
	Cancer	2006	4.0	32.2	1.9	15.8	3.8	31.2	5.0	40.2	5.4	43.9	1.2	9.5	0.2	1.8	0.0	0.1	3.0	24.2
	Osteoporosis	2006	2.9	29.5	1.6	16.8	3.0	31.5	3.8	39.2	3.9	40.5	0.6	6.6	0.1	1.3	0.0	0.1	2.4	24.8
	Osteoarthritis	2006	8.1	32.5	4.2	16.6	8.0	31.9	10.9	43.6	10.6	42.3	2.3	9.2	0.5	1.9	0.0	0.1	6.6	26.2
	Hyperlipidemia	2006	14.6	35.2	7.0	17.0	12.8	31.0	16.2	39.0	18.7	45.1	3.7	8.9	0.8	1.8	0.1	0.1	11.3	27.3
	Cardiovascular disease	2006	12.5	37.8	5.7	17.2	11.1	33.4	16.0	48.2	17.5	52.9	3.5	10.5	0.9	2.8	0.1	0.2	7.0	21.0
Total	All	2007	34.4	33.1	14.9	14.3	29.9	28.8	38.8	37.4	44.4	42.8	8.7	8.3	1.9	1.8	0.3	0.3	26.4	25.4
Age*	Under 65	2007	5.9	35.5	1.8	11.1	4.0	24.0	5.7	34.5	6.5	38.9	1.6	9.5	0.5	2.7	0.0	0.2	3.5	21.1
	65 to 74	2007	12.2	33.7	5.2	14.3	9.7	26.8	12.0	33.0	15.0	41.3	2.9	7.9	0.5	1.4	0.1	0.3	10.5	29.1
	75 to 84	2007	10.8	32.3	5.2	15.7	10.3	30.9	12.8	38.5	15.0	45.0	2.8	8.5	0.6	1.7	0.1	0.3	8.8	26.4
	85 and over	2007	5.5	31.3	2.6	14.8	5.8	33.1	8.3	47.2	7.9	45.1	1.4	7.8	0.3	1.8	0.0	0.2	3.5	20.1
Gender	Male	2007	13.6	36.5	4.5	12.2	9.4	25.3	12.1	32.6	16.0	43.1	4.4	11.9	0.8	2.0	0.1	0.3	7.9	21.2
	Female	2007	20.9	31.3	10.3	15.5	20.5	30.7	26.7	40.1	28.4	42.6	4.3	6.4	1.1	1.7	0.2	0.3	18.5	27.8
Race	White	2007	27.9	33.2	11.7	13.9	22.7	27.0	31.5	37.5	36.5	43.5	6.4	7.6	1.1	1.3	0.2	0.3	20.9	24.9
	Black	2007	4.3	33.8	1.7	13.5	4.8	38.4	5.3	42.3	5.1	40.2	1.7	13.4	0.6	5.0	0.0	0.3	3.7	29.6
	Other	2007	0.4	29.8	0.3	19.3	0.4	31.2	0.4	26.9	0.5	39.8	0.1	8.2	0.0	1.7	0.0	0.4	0.3	25.0
	Asian	2007	0.6	24.2	0.6	25.7	0.9	37.4	0.6	22.6	1.0	39.5	0.2	8.9	0.0	1.5	0.0	0.5	0.6	26.5
	Hispanic	2007	1.1	36.2	0.5	17.3	0.9	29.2	0.9	31.8	1.2	39.0	0.3	8.5	0.1	1.9	0.0	0.3	0.7	24.2

			Antihypertensive Medication Utilization (in 100,000s)																	
			ACE Inhibitors		Angiotensin II Receptor Antagonists		Calcium Channel Blockers		Diuretics		Beta-Blockers		Anti-Adrenergic Agents		Vasodilators		Other Renin-Angiotensin System Antagonists		Combined Therapy	
Breakdown	Category	Year	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
	American Indian/Alaska Native	2007	0.2	44.4	0.1	12.2	0.1	25.5	0.2	38.6	0.2	38.4	0.1	8.9	0.0	1.6	0.0	0.1	0.1	12.4
Comorbid Condition	Diabetes	2007	16.6	40.7	7.0	17.2	12.5	30.7	17.9	43.8	18.9	46.5	4.2	10.2	1.1	2.8	0.2	0.4	10.2	25.0
	Cancer	2007	6.9	31.7	3.2	14.8	6.4	29.5	8.3	37.9	9.7	44.5	1.9	8.7	0.4	1.7	0.1	0.3	5.4	24.5
	Osteoporosis	2007	4.6	29.2	2.5	15.9	4.8	30.1	5.9	37.4	6.5	41.4	1.0	6.0	0.2	1.3	0.1	0.3	3.9	24.9
	Osteoarthritis	2007	12.7	32.2	6.1	15.5	12.0	30.5	16.4	41.8	17.1	43.5	3.4	8.6	0.7	1.9	0.1	0.3	10.3	26.3
	Hyperlipidemia	2007	24.6	34.7	11.1	15.7	20.7	29.3	26.3	37.1	32.3	45.6	5.9	8.3	1.3	1.8	0.2	0.3	19.3	27.3
	Cardiovascular disease	2007	19.5	37.6	8.5	16.3	16.6	32.0	24.0	46.4	28.6	55.1	5.1	9.8	1.5	2.8	0.2	0.4	11.0	21.3
Total	All	2008	35.8	33.3	15.2	14.1	31.4	29.2	39.8	37.0	47.1	43.8	8.8	8.2	2.1	2.0	0.5	0.5	26.6	24.8
Age*	Under 65	2008	6.2	35.8	1.8	10.7	4.2	24.3	5.9	34.2	6.9	39.7	1.6	9.5	0.5	3.0	0.1	0.4	3.5	20.5
	65 to 74	2008	12.8	33.8	5.3	14.0	10.3	27.3	12.3	32.5	15.9	42.0	2.9	7.8	0.6	1.6	0.2	0.5	10.7	28.3
	75 to 84	2008	11.0	32.5	5.3	15.6	10.7	31.5	12.9	38.1	15.7	46.2	2.8	8.4	0.6	1.8	0.2	0.6	8.7	25.8
	85 and over	2008	5.8	31.4	2.8	15.0	6.2	33.6	8.6	46.8	8.6	46.8	1.4	7.6	0.4	2.0	0.1	0.4	3.6	19.7
		2008	14.4	36.7	4.7	12.0	10.1	25.9	12.7	32.4	17.3	44.1	4.5	11.6	0.8	2.2	0.2	0.5	8.1	20.8
Gender	Female	2008	21.4	31.3	10.5	15.3	21.3	31.1	27.1	39.7	29.8	43.6	4.3	6.3	1.3	1.8	0.3	0.5	18.5	27.0
Race	White	2008	29.1	33.3	12.0	13.7	24.0	27.5	32.3	37.0	38.8	44.4	6.5	7.4	1.3	1.4	0.4	0.5	21.1	24.2
	Black	2008	4.3	34.1	1.7	13.4	5.0	39.4	5.4	42.2	5.3	41.6	1.7	13.4	0.7	5.6	0.1	0.6	3.7	29.3
	Other	2008	0.4	29.9	0.3	19.3	0.5	31.4	0.4	26.7	0.6	40.6	0.1	8.1	0.0	1.8	0.0	0.7	0.4	24.8
	Asian	2008	0.6	24.1	0.7	26.0	1.0	37.6	0.6	22.4	1.0	40.2	0.2	8.5	0.0	1.6	0.0	1.1	0.7	26.4
	Hispanic	2008	1.1	36.7	0.5	17.1	0.9	29.7	0.9	31.7	1.2	39.7	0.3	8.4	0.1	2.3	0.0	0.6	0.7	23.4
	American Indian/Alaska Native	2008	0.3	45.1	0.1	12.5	0.1	26.5	0.2	39.1	0.2	39.6	0.1	8.9	0.0	1.8	0.0	0.2	0.1	12.1
Comorbid Condition	Diabetes	2008	17.3	40.4	7.3	17.0	13.4	31.3	18.6	43.3	20.5	47.7	4.3	10.1	1.3	3.0	0.3	0.7	10.4	24.3
	Cancer	2008	7.4	31.9	3.4	14.7	7.0	29.9	8.7	37.5	10.6	45.5	2.0	8.5	0.4	1.8	0.1	0.5	5.6	23.9
	Osteoporosis	2008	5.0	29.5	2.7	15.8	5.2	30.6	6.2	37.0	7.2	42.6	1.0	5.9	0.3	1.5	0.1	0.6	4.1	24.3
	Osteoarthritis	2008	13.3	32.5	6.3	15.4	12.7	31.0	17.0	41.6	18.3	44.7	3.5	8.5	0.9	2.1	0.2	0.6	10.5	25.7
	Hyperlipidemia	2008	26.2	34.8	11.6	15.4	22.4	29.8	27.7	36.8	35.0	46.6	6.2	8.2	1.5	2.0	0.4	0.6	19.9	26.4
	Cardiovascular disease	2008	20.1	37.5	8.7	16.2	17.4	32.5	24.6	46.0	30.3	56.6	5.2	9.7	1.7	3.1	0.4	0.7	11.0	20.6
Total	All	2009	35.9	32.5	15.1	13.6	33.2	30.0	39.8	36.0	48.5	44.0	9.1	8.2	2.4	2.2	0.7	0.6	26.0	23.6
Age*	Under 65	2009	6.4	35.2	1.8	10.1	4.5	24.9	6.1	33.5	7.2	39.8	1.7	9.5	0.6	3.2	0.1	0.5	3.5	19.5
	65 to 74	2009	12.8	32.7	5.2	13.4	11.0	28.2	12.3	31.3	16.4	41.9	3.0	7.7	0.7	1.7	0.2	0.6	10.5	26.9
	75 to 84	2009	10.8	31.8	5.2	15.2	11.1	32.4	12.7	37.3	15.9	46.5	2.9	8.4	0.7	2.1	0.2	0.7	8.4	24.6
	85 and over	2009	5.9	30.9	2.8	14.8	6.6	34.5	8.8	46.1	9.0	47.6	1.5	7.7	0.4	2.3	0.1	0.5	3.6	18.8
		2009	14.6	35.7	4.7	11.6	11.0	26.9	12.9	31.6	18.1	44.3	4.7	11.6	1.0	2.4	0.2	0.6	8.1	19.8
Gender	Female	2009	21.3	30.6	10.3	14.9	22.2	31.9	26.9	38.7	30.5	43.8	4.3	6.2	1.5	2.1	0.4	0.6	17.9	25.8

			Antihypertensive Medication Utilization (in 100,000s)																	
			ACE Inhibitors		Angiotensin II Receptor Antagonists		Calcium Channel Blockers		Diuretics		Beta-Blockers		Anti-Adrenergic Agents		Vasodilators		Other Renin-Angiotensin System Antagonists		Combined Therapy	
Breakdown	Category	Year	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Race	White	2009	28.9	32.4	11.8	13.2	25.2	28.2	32.1	36.0	39.8	44.5	6.7	7.4	1.4	1.6	0.5	0.6	20.5	22.9
	Black	2009	4.5	33.9	1.7	13.1	5.3	40.6	5.5	41.6	5.6	42.3	1.8	13.4	0.8	6.2	0.1	0.7	3.7	28.3
	Other	2009	0.5	29.5	0.3	19.1	0.5	31.9	0.4	26.2	0.6	41.0	0.1	8.0	0.0	2.1	0.0	0.9	0.4	23.9
	Asian	2009	0.6	23.8	0.7	26.1	1.0	38.1	0.6	22.3	1.1	40.7	0.2	8.4	0.1	1.8	0.0	1.3	0.7	25.3
	Hispanic	2009	1.1	36.6	0.5	16.9	1.0	30.4	1.0	31.5	1.3	40.0	0.3	8.5	0.1	2.6	0.0	0.8	0.7	22.6
	American Indian/Alaska Native	2009	0.3	44.4	0.1	11.9	0.2	27.4	0.2	39.1	0.2	40.5	0.1	9.1	0.0	2.0	0.0	0.3	0.1	11.7
Comorbid Condition	Diabetes	2009	17.5	39.1	7.3	16.3	14.4	32.2	18.9	42.3	21.5	48.0	4.5	10.1	1.5	3.3	0.4	0.8	10.4	23.2
	Cancer	2009	7.6	31.2	3.5	14.2	7.5	30.7	8.9	36.6	11.1	45.6	2.1	8.5	0.5	2.0	0.2	0.6	5.5	22.8
	Osteoporosis	2009	5.1	29.0	2.7	15.4	5.5	31.5	6.3	36.2	7.5	42.8	1.0	6.0	0.3	1.7	0.1	0.7	4.1	23.2
	Osteoarthritis	2009	13.6	32.0	6.3	14.9	13.5	31.7	17.3	40.8	19.1	45.0	3.6	8.5	1.0	2.4	0.3	0.7	10.4	24.5
	Hyperlipidemia	2009	26.7	33.9	11.7	14.8	24.2	30.7	28.4	35.9	36.8	46.6	6.5	8.2	1.8	2.2	0.6	0.7	19.8	25.0
	Cardiovascular disease	2009	20.0	36.5	8.6	15.6	18.2	33.2	24.8	45.3	31.2	56.9	5.4	9.8	1.9	3.4	0.4	0.8	10.7	19.5

Table 3. Proportion of Medicare Parts A, B, and D Beneficiaries With Hypertension and Use of One or More Antihypertensive Drugs, by Hospital Referral Region; Adjusted by Age Category, Gender, Race, and Comorbid Conditions, 2006-2009

Hospital Referral Region	Adjusted Percentage of Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
	2006	2007	2008	2009
1	86.7	84.6	85.4	85.7
2	90.4	89.0	89.2	88.8
5	90.4	89.2	89.6	88.7
6	89.8	88.5	88.3	87.8
7	88.9	88.5	88.6	88.0
9	88.5	87.2	87.3	87.5
10	89.0	89.2	89.9	89.2
11	88.3	87.2	87.5	86.7
12	87.1	86.5	87.2	86.6
14	86.3	85.2	85.5	84.7
15	87.3	87.1	87.4	87.0
16	90.7	89.7	89.1	87.6
18	92.0	91.0	91.2	90.2
19	90.7	89.6	89.9	88.6
21	91.3	89.8	89.3	87.6
22	90.8	89.6	89.8	88.2
23	85.4	84.4	84.5	85.3
25	86.3	85.9	85.7	86.4
31	87.5	86.5	86.6	87.1
33	86.9	85.8	86.2	86.9
43	86.5	85.8	85.7	86.3
56	82.5	82.6	82.8	83.2
58	88.7	88.0	87.7	87.8
62	86.3	85.7	85.4	86.7
65	85.7	85.4	86.0	86.2
69	83.8	82.3	83.2	83.6
73	88.2	87.0	87.1	87.7
77	87.6	87.1	87.2	87.6
78	86.2	84.5	84.0	85.9
79	84.6	85.2	85.0	85.2
80	85.4	85.4	85.4	85.8
81	86.2	86.2	86.2	87.0
82	88.3	87.6	87.8	88.5
83	88.5	87.0	86.0	86.4
85	85.4	84.7	84.5	86.2
86	84.9	84.1	84.3	84.9
87	87.1	86.4	86.0	87.1
89	86.3	85.3	85.4	86.9
91	88.8	87.8	87.3	87.6

	Adjusted Percentage of Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
96	85.2	84.2	84.1	84.8
101	89.3	88.3	88.4	87.3
102	89.6	89.0	88.2	86.3
103	89.8	89.2	89.8	88.7
104	90.7	90.2	90.4	90.0
105	89.4	89.6	90.8	89.1
106	91.2	90.0	90.4	89.1
107	88.5	87.1	86.9	85.8
109	85.0	84.2	84.2	84.7
110	87.2	87.4	87.7	87.2
111	86.9	86.5	86.8	86.6
112	86.4	85.9	85.8	84.9
113	87.0	85.9	86.5	86.2
115	84.3	83.4	83.1	82.0
116	85.0	84.6	84.7	84.5
118	83.5	81.9	82.5	82.3
119	86.7	85.5	85.4	85.0
120	87.8	87.1	87.6	86.8
122	85.4	84.1	84.0	83.1
123	88.3	87.6	88.0	86.9
124	87.7	87.0	86.8	85.5
127	82.9	82.4	83.3	83.7
129	86.7	86.0	85.9	84.4
130	86.0	85.3	85.3	84.3
131	85.0	84.7	84.3	83.2
133	89.3	87.7	87.0	87.5
134	89.3	88.1	87.8	86.9
137	85.8	84.8	85.1	84.7
139	85.1	84.7	84.7	84.5
140	88.8	87.7	87.6	87.0
141	86.9	85.9	86.3	85.4
142	90.0	88.7	89.5	88.0
144	88.9	88.5	88.6	87.9
145	89.0	88.2	88.3	88.0
146	88.2	87.0	87.5	86.4
147	88.4	87.3	87.7	87.5
148	90.2	89.8	89.8	89.2
149	88.6	87.4	87.5	86.7
150	82.8	81.2	82.1	82.3
151	90.2	89.6	90.2	89.7
152	89.6	88.7	88.7	88.5

	Adjusted Percentage of Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
154	89.8	89.6	90.0	89.0
155	85.6	86.2	86.5	85.4
156	84.0	85.0	85.1	84.8
158	89.2	89.2	89.4	88.3
161	88.4	88.0	88.3	87.8
163	88.8	89.6	89.0	88.7
164	87.9	88.6	88.4	87.2
166	88.3	88.4	88.3	87.6
170	89.9	90.2	90.5	89.7
171	90.8	91.3	91.3	90.2
172	91.5	91.3	91.3	90.2
173	90.3	90.3	90.2	89.1
175	90.7	91.2	90.9	90.0
179	91.7	90.7	90.5	89.3
180	91.7	91.0	90.9	89.5
181	89.1	88.1	88.4	87.4
183	91.6	90.7	90.5	89.4
184	91.2	91.1	90.8	89.2
185	91.6	91.4	91.0	89.6
186	87.5	86.5	86.9	86.3
187	90.7	89.6	89.5	88.3
188	92.2	91.1	91.2	89.9
190	93.7	92.5	92.6	92.0
191	90.3	90.2	90.4	89.4
192	92.5	91.2	91.4	90.7
193	91.5	90.1	90.5	89.3
194	92.2	90.7	91.1	90.3
195	94.1	92.4	92.7	91.6
196	92.8	91.5	91.9	91.6
197	92.7	91.7	91.9	91.3
200	90.1	89.6	90.2	89.2
201	91.7	90.4	90.5	89.7
203	91.6	90.3	90.4	89.1
204	91.6	90.7	90.7	89.9
205	91.1	90.1	90.2	89.4
207	89.9	88.3	87.9	87.3
208	91.1	90.3	89.4	88.8
209	88.9	89.2	89.2	87.5
210	88.0	88.9	88.6	87.8
212	89.5	90.4	90.4	89.4
213	88.0	88.5	88.6	88.0

	Adjusted Percentage of Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
214	87.6	88.7	89.2	87.6
216	87.2	89.0	88.7	88.0
217	89.1	89.3	89.1	88.1
218	85.5	87.2	87.0	86.5
219	87.9	88.1	88.3	87.1
220	88.5	89.8	89.7	89.3
221	89.8	90.0	89.9	89.4
222	89.4	89.2	89.3	88.6
223	87.2	86.5	86.4	86.1
225	88.1	87.1	86.7	86.0
226	85.8	84.3	85.1	85.4
227	88.9	88.7	89.0	88.9
230	90.0	89.5	89.4	88.9
231	88.3	88.1	88.3	87.7
232	87.6	86.8	86.8	86.3
233	84.9	83.8	84.0	83.5
234	85.1	84.1	84.6	84.6
235	84.7	83.9	84.4	84.7
236	90.9	89.6	89.4	88.6
238	90.7	90.3	90.2	89.1
239	90.3	89.1	88.9	87.9
240	90.9	90.1	90.0	89.3
242	89.9	88.5	88.5	87.2
243	89.4	88.2	87.9	87.3
244	84.0	82.7	83.1	82.8
245	84.2	82.5	83.1	82.6
246	89.1	88.0	88.3	87.0
248	90.3	89.3	89.0	87.9
249	89.4	87.5	88.2	87.2
250	92.1	91.6	92.1	91.6
251	92.6	91.5	92.0	91.5
253	93.7	92.5	92.8	92.3
254	92.8	91.7	92.6	91.7
256	92.3	91.6	92.0	91.1
257	88.1	88.1	88.1	88.3
258	91.3	90.6	90.4	90.5
259	90.4	89.2	89.5	89.4
260	90.4	89.5	90.1	89.5
261	91.6	90.5	91.0	90.7
262	91.9	91.1	90.9	89.9
263	91.3	90.3	90.6	89.4


	Adjusted Percentage of Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
264	90.4	89.9	89.8	88.4
267	89.7	89.4	89.3	87.6
268	90.5	89.7	89.5	88.2
270	91.2	90.4	90.4	89.0
273	89.8	89.3	89.4	88.8
274	91.4	90.8	91.5	90.5
275	90.1	89.4	89.7	88.8
276	90.2	89.1	89.8	89.4
277	92.3	91.0	91.0	90.1
278	91.9	91.0	91.3	90.6
279	85.5	84.2	84.8	84.2
280	88.1	87.8	87.3	87.3
281	91.2	90.4	90.3	89.5
282	89.5	89.3	88.9	87.7
283	85.4	84.3	84.7	84.4
284	83.7	82.5	83.2	83.3
285	86.2	85.1	85.5	85.4
288	85.1	84.5	85.3	85.0
289	83.6	82.4	83.0	82.9
291	85.6	84.4	84.8	84.5
292	83.1	82.4	83.3	83.4
293	88.7	88.7	88.5	86.8
295	87.5	86.7	87.4	87.3
296	89.2	88.7	89.2	89.8
297	85.0	84.3	84.6	85.3
299	88.0	87.0	88.0	87.7
300	87.9	87.2	87.7	87.7
301	81.6	80.5	81.6	82.2
303	84.4	83.2	83.2	83.9
304	88.2	88.0	88.3	88.3
307	87.3	87.2	88.4	88.1
308	82.5	82.4	83.8	83.8
309	92.0	91.6	91.3	89.7
311	90.9	90.8	90.6	89.2
312	91.2	90.3	90.1	88.9
313	90.5	89.9	89.8	88.5
314	91.7	90.7	90.5	89.8
315	91.8	91.1	91.0	89.7
318	91.2	89.8	90.1	88.8
319	89.8	88.6	88.5	87.9
320	91.1	90.3	90.3	89.1

	Adjusted Percentage of Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
321	92.1	91.0	91.5	91.9
322	92.8	92.0	92.5	92.2
323	93.3	92.2	92.6	92.7
324	91.8	91.0	91.9	92.4
325	87.7	87.1	87.1	86.9
326	90.3	89.6	89.7	89.0
327	89.2	88.9	88.8	88.4
328	88.0	87.7	87.7	87.4
329	90.4	89.5	89.5	88.9
330	89.8	89.4	89.0	87.8
331	89.0	87.7	88.4	87.6
332	89.5	88.9	88.4	87.6
334	89.4	88.7	88.8	85.1
335	86.6	85.5	86.0	85.1
336	89.1	89.2	89.4	87.9
339	89.6	89.3	88.8	87.7
340	89.8	89.3	89.1	87.8
341	90.6	89.2	89.8	88.3
342	89.8	89.3	89.5	88.6
343	88.7	87.6	87.6	86.9
344	90.5	89.9	90.5	90.1
345	90.5	90.9	91.0	90.1
346	86.5	87.1	87.0	86.7
347	88.9	88.7	88.6	88.1
350	88.9	89.0	89.1	88.4
351	88.5	88.4	88.5	87.2
352	89.0	89.2	89.0	88.6
354	87.8	87.9	87.9	88.1
355	87.2	87.9	88.4	87.8
356	84.0	84.1	84.4	84.6
357	86.7	86.7	86.8	86.2
358	86.3	86.7	87.1	87.0
359	89.8	90.0	90.7	89.6
360	86.2	86.6	86.7	86.0
362	86.8	86.9	86.8	86.5
363	89.4	89.8	89.3	88.4
364	88.1	87.6	87.7	87.4
365	89.5	88.3	87.9	86.8
366	90.1	89.3	89.1	87.6
367	92.0	91.2	90.8	89.8
368	90.4	89.2	89.1	87.3


	Adjusted Percentage of Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
369	91.1	90.6	90.2	89.0
370	92.0	90.4	91.0	90.8
371	93.3	91.9	92.5	92.0
373	90.0	89.7	89.7	88.4
374	91.0	90.6	90.5	89.7
375	90.4	90.2	90.4	89.5
376	91.2	90.9	91.2	90.5
377	91.1	90.8	90.7	90.0
379	90.1	89.4	89.7	89.2
380	90.7	90.3	90.2	89.6
382	90.0	89.5	89.1	87.7
383	91.3	90.6	90.3	88.8
385	88.0	88.5	88.0	87.6
386	87.0	87.6	86.8	85.9
388	89.0	88.1	88.6	86.3
390	86.7	85.8	86.2	85.0
391	88.3	88.0	87.8	86.7
393	85.7	85.1	85.4	83.9
394	89.2	88.6	88.4	87.4
396	84.8	84.1	84.4	84.3
397	88.3	88.2	88.0	87.3
399	89.1	89.2	88.6	87.1
400	89.9	89.2	89.0	87.6
402	82.7	82.0	82.4	83.1
406	89.4	89.1	88.6	86.9
411	91.3	89.6	88.7	86.7
412	85.4	85.6	85.7	85.1
413	88.4	88.3	87.3	85.1
416	89.1	88.6	88.8	87.4
417	90.4	89.4	88.9	87.9
418	89.7	89.8	88.8	88.1
420	89.6	89.5	89.3	88.0
421	89.1	88.0	88.3	87.4
422	89.7	88.5	88.4	88.8
423	89.9	89.2	89.8	89.0
424	90.1	89.4	89.4	89.3
426	87.8	87.3	88.0	87.7
427	90.5	90.4	90.5	89.2
428	92.1	91.5	91.0	89.7
429	90.0	89.2	89.0	88.1
430	88.1	87.6	88.1	87.4

	Adjusted Percentage of Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
431	89.0	88.9	89.3	88.2
432	90.4	89.8	89.8	88.6
435	90.6	90.4	90.4	89.2
437	90.8	89.5	90.1	90.0
438	88.9	87.9	88.8	87.7
439	90.2	89.1	89.9	89.9
440	90.4	89.1	89.6	88.9
441	89.6	89.2	89.7	89.6
442	90.8	89.8	90.4	89.2
443	89.7	89.2	89.7	89.0
444	90.1	89.4	89.8	89.0
445	90.1	89.2	89.0	88.4
446	90.4	90.8	90.9	90.2
447	92.2	92.0	92.0	91.0
448	93.6	93.7	93.8	92.8
449	92.6	92.4	92.6	92.4
450	93.3	92.8	92.8	92.3
451	90.4	90.3	90.5	89.8
452	92.2	91.9	92.0	91.9
456	93.2	92.3	91.9	92.0
457	92.4	91.0	91.8	91.4


Table 4. Dartmouth Atlas of Health Care Maps of the Proportion of Medicare Parts A, B, and D Beneficiaries With Hypertension and Use of One or More Antihypertensive Drugs, by Hospital Referral Region (HRR); Adjusted by Age Category, Gender, Race, and Comorbid Conditions, 2006-2009



Proportion (%) of Hypertensive Beneficiaries with Antihypertensive Drug Use
2007



Proportion (%) of Hypertensive Beneficiaries with Antihypertensive Drug Use
2008



Proportion (%) of Hypertensive Beneficiaries with Antihypertensive Drug Use
2009




Table 5. Proportion of Medicare Parts A, B, and D Beneficiaries With Hypertension and Use of One or More Antihypertensive Drugs, by Hospital Referral Region (HRR) and Race; Adjusted by Age Category, Gender, and Comorbid Conditions, 2009

Note: An asterisk (*) indicates a small cell count (<11).

	Beneficiaries With Hypertension and Any Antihypertensive Medication Use					
	White	Black	Asian	Hispanic	American Indian/Alaska Native	Other Race
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
1	85.8%	88.4%	84.5%	76.2%	86.6%	83.0%
2	88.4%	90.8%	92.6%	86.5%	86.2%	94.1%
5	88.6%	90.1%	85.9%	89.4%	*	85.5%
6	87.5%	89.8%	86.4%	88.2%	81.5%	84.9%
7	87.8%	89.6%	93.3%	*	*	90.3%
9	87.0%	89.3%	*	*	*	89.2%
10	88.6%	88.3%	91.1%	89.8%	87.8%	88.3%
11	86.2%	90.7%	85.7%	90.2%	91.7%	87.6%
12	86.0%	86.4%	89.7%	87.5%	87.5%	87.6%
14	84.5%	83.1%	85.5%	89.2%	63.2%	78.4%
15	86.9%	85.3%	88.8%	88.5%	78.0%	83.7%
16	87.6%	91.6%	87.4%	74.8%	79.0%	91.4%
18	90.0%	92.4%	95.9%	95.6%	79.4%	86.7%
19	88.2%	90.7%	90.4%	84.6%	81.0%	86.1%
21	87.4%	92.0%	85.4%	84.6%	80.4%	86.1%
22	87.9%	89.7%	79.9%	83.2%	87.5%	88.6%
23	84.5%	86.0%	88.9%	86.3%	84.4%	84.9%
25	86.1%	88.9%	88.3%	86.5%	85.2%	86.1%
31	86.8%	90.1%	80.6%	88.6%	84.7%	85.0%
33	86.8%	86.7%	89.4%	88.2%	82.8%	84.4%
43	85.9%	87.5%	86.7%	86.9%	86.4%	88.0%
56	83.0%	83.0%	86.0%	84.4%	77.5%	83.4%
58	87.4%	90.3%	89.4%	88.4%	84.0%	90.2%
62	86.2%	86.3%	86.9%	89.3%	88.6%	85.1%
65	85.3%	87.5%	89.4%	86.8%	77.6%	87.4%
69	83.2%	87.3%	89.5%	84.5%	75.7%	81.6%
73	87.3%	92.2%	90.0%	88.0%	88.6%	87.3%
77	87.2%	90.1%	89.2%	88.7%	83.6%	87.7%
78	85.9%	83.2%	86.1%	86.9%	74.7%	83.9%
79	84.8%	86.8%	88.3%	86.0%	78.7%	83.8%
80	85.1%	87.2%	89.3%	87.1%	72.4%	86.9%
81	85.9%	89.5%	89.4%	89.3%	84.1%	87.3%
82	87.5%	89.9%	91.5%	87.3%	75.8%	89.0%
83	86.3%	93.5%	88.4%	82.8%	80.9%	80.1%

	Beneficiaries With Hypertension and Any Antihypertensive Medication Use					
	White	Black	Asian	Hispanic	American Indian/Alaska Native	Other Race
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
85	85.8%	89.9%	87.9%	87.8%	94.1%	86.6%
86	84.4%	89.4%	88.6%	84.6%	89.2%	86.3%
87	87.2%	91.1%	87.6%	84.2%	76.5%	84.9%
89	86.5%	88.7%	86.0%	87.2%	91.6%	84.4%
91	87.7%	88.3%	90.5%	85.7%	81.2%	87.6%
96	84.2%	87.4%	89.0%	85.9%	94.5%	85.7%
101	87.1%	82.1%	85.2%	86.5%	87.4%	94.6%
102	86.2%	85.1%	84.0%	86.2%	89.2%	84.0%
103	88.5%	88.8%	89.5%	89.0%	87.1%	86.6%
104	89.9%	89.4%	86.1%	85.1%	91.3%	93.7%
105	88.8%	89.2%	80.9%	90.6%	74.7%	89.2%
106	88.9%	88.3%	76.0%	88.8%	96.6%	88.8%
107	85.4%	87.4%	89.9%	86.6%	*	89.3%
109	84.1%	88.4%	84.9%	86.2%	*	83.8%
110	86.9%	89.4%	87.8%	88.6%	82.9%	88.6%
111	86.1%	89.2%	88.8%	90.5%	87.8%	87.3%
112	84.6%	86.9%	85.5%	86.5%	94.3%	83.9%
113	86.5%	86.9%	87.5%	86.5%	88.3%	85.4%
115	81.6%	85.6%	84.6%	84.5%	*	82.0%
118	81.8%	85.9%	83.5%	83.1%	87.5%	81.9%
119	84.7%	86.7%	85.7%	87.5%	78.3%	86.1%
120	86.4%	89.1%	90.8%	84.5%	93.4%	82.8%
122	82.8%	82.2%	82.1%	83.0%	76.8%	83.4%
123	86.9%	88.0%	88.7%	83.8%	83.4%	82.8%
124	85.3%	87.3%	84.7%	86.3%	88.1%	75.0%
127	82.6%	85.3%	85.2%	85.4%	74.6%	84.7%
129	84.2%	86.1%	86.3%	84.0%	73.3%	79.0%
130	84.0%	87.1%	86.6%	84.1%	83.8%	84.0%
131	83.0%	84.6%	83.6%	82.9%	*	78.5%
133	87.3%	88.7%	84.2%	92.1%	*	87.0%
134	86.6%	89.1%	86.6%	80.7%	76.9%	83.0%
137	84.3%	88.4%	87.6%	86.1%	*	78.5%
139	84.0%	88.3%	85.3%	85.1%	75.3%	86.8%
140	86.6%	88.9%	86.2%	84.6%	*	87.1%
141	85.0%	88.1%	89.3%	85.6%	76.7%	87.5%
142	87.5%	90.0%	100.0%	100.0%	*	83.5%
144	87.8%	89.2%	87.7%	86.4%	82.0%	86.0%

	Beneficiaries With Hypertension and Any Antihypertensive Medication Use					
	White	Black	Asian	Hispanic	American Indian/Alaska Native	Other Race
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
145	87.3%	90.4%	82.6%	73.1%	100.0%	89.9%
146	85.7%	88.7%	91.9%	86.0%	90.1%	91.9%
147	86.8%	89.8%	86.9%	86.9%	92.2%	90.8%
148	89.0%	90.0%	94.2%	88.9%	*	87.3%
149	86.4%	88.7%	81.6%	89.3%	86.7%	83.7%
150	82.6%	84.0%	83.6%	87.5%	79.2%	82.6%
151	89.6%	92.4%	89.4%	87.8%	72.6%	87.7%
152	88.4%	95.0%	85.3%	80.3%	88.5%	86.0%
154	89.1%	86.9%	94.8%	87.0%	*	89.2%
155	86.1%	84.0%	89.1%	80.7%	*	84.8%
156	86.2%	84.9%	85.3%	84.8%	78.9%	85.9%
158	88.5%	86.8%	86.3%	81.0%	*	84.2%
161	87.8%	88.3%	87.0%	85.3%	90.0%	85.0%
163	88.8%	88.8%	87.0%	86.0%	*	84.8%
164	87.2%	87.1%	89.1%	85.0%	90.1%	84.0%
166	87.8%	87.6%	86.8%	83.9%	79.5%	81.8%
170	89.5%	90.1%	93.1%	85.3%	*	88.2%
171	90.0%	91.4%	91.9%	89.0%	85.2%	94.0%
172	90.0%	91.0%	88.3%	88.9%	86.9%	85.5%
173	88.9%	90.0%	91.2%	83.9%	*	87.2%
175	90.0%	88.1%	85.4%	74.0%	*	89.3%
179	89.1%	91.7%	88.3%	85.2%	93.2%	86.3%
180	89.3%	89.1%	86.9%	85.6%	*	84.7%
181	87.8%	86.8%	79.6%	78.8%	74.2%	89.1%
183	89.3%	89.6%	90.9%	86.9%	88.0%	88.0%
184	88.9%	90.4%	92.4%	95.4%	*	94.1%
185	89.4%	89.6%	81.9%	*	*	92.1%
186	86.6%	86.5%	93.6%	78.3%	*	76.5%
187	88.0%	89.9%	84.8%	86.6%	87.7%	88.3%
188	89.9%	87.3%	92.1%	*	*	82.0%
190	91.8%	92.9%	97.3%	96.0%	*	89.6%
191	89.1%	91.2%	91.5%	86.3%	100.0%	92.6%
192	90.5%	89.5%	91.2%	90.0%	83.5%	88.4%
193	89.0%	95.3%	93.4%	*	*	77.8%
194	90.1%	92.3%	93.0%	88.4%	*	85.4%
195	91.5%	89.9%	89.2%	*	*	85.0%
196	91.5%	91.2%	81.5%	93.5%	83.4%	88.5%

	Beneficiaries With Hypertension and Any Antihypertensive Medication Use					
	White	Black	Asian	Hispanic	American Indian/Alaska Native	Other Race
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
197	91.3%	90.1%	93.9%	*	*	90.3%
200	89.0%	89.9%	90.4%	87.3%	87.5%	83.7%
201	89.5%	90.4%	92.0%	85.6%	85.1%	86.4%
203	88.8%	90.9%	87.5%	100.0%	*	93.5%
204	89.7%	90.8%	84.5%	82.8%	87.3%	91.6%
205	89.2%	90.6%	90.6%	91.4%	86.9%	89.5%
207	87.1%	88.6%	*	*	*	90.7%
208	88.4%	92.0%	92.2%	81.8%	92.5%	91.1%
209	86.9%	90.0%	80.4%	93.6%	88.2%	85.9%
210	87.6%	89.3%	90.4%	88.5%	79.8%	91.8%
212	89.8%	88.2%	83.6%	83.3%	84.1%	86.4%
213	87.6%	89.9%	87.7%	85.1%	71.9%	89.6%
214	87.4%	89.3%	77.3%	80.0%	*	78.8%
216	87.6%	89.9%	89.8%	88.9%	*	89.0%
217	87.8%	89.9%	94.5%	80.4%	*	90.7%
218	87.6%	87.2%	87.3%	89.7%	72.0%	88.0%
219	86.8%	88.9%	91.1%	89.0%	87.3%	86.6%
220	89.0%	91.0%	87.2%	91.1%	*	96.5%
221	89.1%	89.1%	84.4%	100.0%	88.6%	89.8%
222	88.3%	89.6%	88.7%	88.2%	91.4%	89.0%
223	85.7%	88.6%	84.4%	83.5%	79.1%	84.3%
225	85.6%	88.6%	86.1%	82.9%	86.2%	83.3%
226	86.0%	85.4%	87.5%	85.2%	80.2%	86.9%
227	88.3%	91.6%	91.8%	92.7%	87.8%	90.4%
230	88.4%	90.9%	91.9%	92.8%	90.3%	90.1%
231	87.3%	90.6%	91.2%	88.0%	80.2%	88.6%
232	86.1%	87.4%	86.2%	87.0%	94.3%	85.6%
233	83.3%	84.2%	85.9%	78.0%	76.4%	84.1%
234	84.8%	85.5%	84.3%	84.1%	81.9%	85.7%
235	84.3%	86.9%	84.5%	81.2%	86.7%	88.9%
236	88.2%	90.7%	88.5%	89.7%	84.3%	91.5%
238	88.9%	91.2%	82.9%	88.8%	86.6%	85.2%
239	87.5%	92.1%	87.1%	88.5%	76.0%	87.6%
240	89.0%	87.8%	*	*	83.0%	100.0%
242	86.7%	89.7%	90.2%	89.9%	86.0%	87.0%
243	86.9%	84.6%	*	*	87.0%	85.9%
244	82.7%	83.6%	82.5%	83.2%	91.4%	77.7%

	Beneficiaries With Hypertension and Any Antihypertensive Medication Use					
	White	Black	Asian	Hispanic	American Indian/Alaska Native	Other Race
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
245	82.2%	83.9%	86.2%	80.3%	82.7%	84.0%
246	86.7%	89.7%	92.3%	83.6%	83.5%	87.5%
248	87.9%	88.4%	92.0%	94.4%	88.7%	77.0%
249	86.9%	90.1%	*	88.4%	89.9%	97.4%
250	91.3%	89.9%	94.7%	*	92.5%	96.1%
251	91.2%	93.1%	91.8%	93.2%	90.1%	91.8%
253	92.2%	87.9%	91.5%	77.6%	100.0%	91.2%
254	91.4%	93.3%	100.0%	95.3%	92.3%	94.5%
256	90.7%	93.6%	95.7%	87.5%	83.6%	91.6%
257	88.0%	90.5%	89.7%	77.4%	*	79.8%
258	89.8%	93.0%	94.7%	*	71.8%	90.9%
259	88.6%	91.6%	93.3%	85.8%	84.0%	87.6%
260	89.1%	91.5%	87.7%	*	75.1%	100.0%
261	89.9%	93.2%	*	*	*	87.8%
262	89.3%	92.5%	89.2%	*	89.7%	89.3%
263	89.1%	92.1%	91.7%	78.3%	100.0%	78.7%
264	88.0%	92.2%	87.8%	83.6%	85.5%	91.2%
267	87.6%	91.5%	88.9%	89.1%	77.1%	85.0%
268	87.9%	90.1%	87.5%	82.2%	81.6%	86.5%
270	88.8%	91.4%	95.1%	93.1%	84.4%	88.0%
273	88.7%	89.7%	86.1%	87.6%	85.6%	86.7%
274	90.5%	90.6%	92.7%	81.1%	79.4%	88.4%
275	89.3%	89.2%	*	*	78.3%	95.1%
276	89.2%	84.1%	76.1%	92.1%	85.3%	91.4%
277	89.8%	94.1%	95.2%	87.4%	87.7%	85.8%
278	90.4%	91.3%	87.3%	86.6%	83.9%	91.4%
279	83.6%	86.1%	88.1%	86.9%	74.0%	85.7%
280	87.3%	87.2%	86.6%	85.0%	79.2%	85.9%
281	89.3%	94.8%	95.4%	93.7%	*	88.3%
282	87.4%	90.1%	86.9%	84.9%	94.3%	93.1%
283	83.9%	88.2%	86.2%	86.4%	82.4%	85.7%
284	82.8%	85.9%	85.1%	85.2%	93.7%	82.6%
285	85.3%	86.6%	86.6%	85.1%	78.0%	83.4%
288	84.7%	88.5%	85.8%	86.4%	90.3%	82.8%
289	82.8%	84.5%	86.7%	81.9%	78.5%	84.0%
291	84.0%	87.6%	85.1%	85.0%	*	83.4%
292	83.0%	85.0%	86.7%	84.7%	93.2%	84.7%


	Beneficiaries With Hypertension and Any Antihypertensive Medication Use					
	White	Black	Asian	Hispanic	American Indian/Alaska Native	Other Race
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
293	86.4%	88.6%	94.4%	85.6%	85.7%	86.3%
295	87.0%	89.5%	85.6%	86.7%	80.4%	87.0%
296	89.7%	90.1%	87.3%	95.1%	*	81.2%
297	83.1%	87.1%	91.1%	89.3%	88.6%	86.2%
299	87.5%	89.5%	88.1%	86.6%	83.3%	85.3%
300	87.6%	87.3%	87.9%	80.6%	*	85.5%
301	81.1%	85.4%	87.4%	86.0%	85.5%	84.8%
303	82.4%	86.4%	88.8%	87.7%	84.0%	86.6%
304	87.7%	91.1%	90.6%	90.7%	75.9%	88.6%
307	87.9%	89.4%	90.3%	86.6%	59.8%	87.2%
308	83.4%	86.6%	85.3%	84.6%	80.7%	81.8%
309	89.5%	92.9%	93.5%	87.8%	82.5%	90.2%
311	89.0%	90.6%	88.6%	88.2%	81.8%	89.6%
312	88.2%	91.2%	91.3%	89.0%	86.3%	89.7%
313	88.7%	88.4%	96.0%	78.8%	90.7%	83.1%
314	89.1%	92.0%	90.1%	87.8%	91.7%	88.7%
315	89.5%	92.0%	86.9%	91.1%	*	86.3%
318	88.5%	90.5%	87.1%	85.8%	83.9%	87.2%
319	87.1%	91.0%	89.6%	85.0%	92.5%	86.8%
320	88.9%	90.5%	88.5%	89.7%	90.9%	88.9%
321	91.7%	93.0%	*	*	89.4%	93.9%
322	92.1%	94.8%	96.9%	92.5%	89.2%	90.4%
323	92.5%	86.1%	*	85.8%	90.3%	89.2%
324	92.4%	*	*	*	86.7%	87.0%
325	86.7%	88.2%	91.4%	76.5%	*	93.4%
326	88.9%	88.8%	85.8%	91.2%	*	87.7%
327	88.3%	89.6%	85.6%	87.1%	86.7%	86.3%
328	87.3%	88.3%	89.0%	90.9%	88.3%	87.3%
329	88.7%	89.4%	89.6%	89.1%	89.9%	86.7%
330	87.8%	87.5%	84.0%	86.1%	89.5%	87.2%
331	87.6%	87.9%	95.2%	86.5%	*	76.6%
332	87.5%	85.9%	88.6%	83.6%	*	86.1%
334	84.9%	86.4%	86.6%	85.2%	79.6%	86.4%
335	84.8%	87.4%	85.3%	88.8%	*	81.3%
336	87.6%	87.1%	79.6%	90.4%	87.4%	87.0%
339	87.4%	89.8%	89.0%	85.9%	84.9%	82.9%
340	87.6%	90.2%	91.7%	91.6%	82.9%	86.3%

	Beneficiaries With Hypertension and Any Antihypertensive Medication Use					
	White	Black	Asian	Hispanic	American Indian/Alaska Native	Other Race
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
341	88.2%	95.0%	*	89.8%	80.3%	88.8%
342	88.4%	90.0%	91.9%	82.7%	80.5%	90.4%
343	86.7%	83.6%	79.0%	85.6%	85.5%	87.6%
344	89.8%	91.6%	92.4%	89.5%	85.3%	92.2%
345	90.1%	88.8%	92.1%	82.2%	72.9%	96.2%
346	86.4%	88.5%	85.3%	88.2%	89.5%	85.6%
347	87.8%	88.2%	*	*	*	93.2%
350	88.1%	90.7%	83.0%	94.9%	*	92.1%
351	87.0%	91.3%	77.0%	85.4%	82.0%	86.7%
352	88.4%	89.0%	87.4%	86.1%	*	88.1%
354	87.9%	91.9%	*	*	*	73.8%
355	87.6%	87.3%	86.7%	92.7%	*	85.5%
356	84.1%	87.1%	88.5%	83.7%	81.0%	85.1%
357	86.0%	86.5%	85.7%	85.4%	83.3%	84.6%
358	86.8%	86.4%	90.7%	87.0%	*	87.2%
359	89.4%	91.5%	92.3%	*	*	93.0%
360	85.7%	89.7%	82.6%	85.8%	70.1%	93.0%
362	86.2%	91.3%	91.7%	85.6%	*	83.7%
363	88.2%	87.9%	86.3%	90.3%	*	89.0%
364	87.0%	89.7%	90.8%	91.1%	89.0%	86.7%
365	86.6%	88.4%	85.8%	85.8%	88.0%	82.5%
366	87.3%	89.6%	74.4%	88.6%	95.8%	86.0%
367	89.1%	91.7%	97.1%	96.9%	93.4%	89.3%
368	86.8%	90.5%	90.8%	84.9%	90.0%	87.6%
369	88.8%	90.4%	84.8%	81.8%	*	89.7%
370	90.8%	100.0%	*	87.6%	85.7%	90.2%
371	91.8%	93.9%	94.3%	94.0%	84.3%	95.0%
373	88.2%	89.8%	85.8%	84.1%	88.7%	86.5%
374	89.5%	91.0%	75.1%	83.4%	*	88.3%
375	89.4%	87.0%	*	*	*	84.4%
376	90.3%	90.3%	91.0%	81.3%	*	84.7%
377	89.9%	90.3%	88.9%	86.7%	81.0%	91.9%
379	89.0%	90.8%	90.0%	88.3%	80.9%	86.9%
380	89.4%	91.0%	87.5%	86.0%	90.3%	89.8%
382	87.5%	88.5%	73.2%	87.2%	79.2%	89.3%
383	88.8%	91.2%	86.1%	85.7%	88.4%	85.3%
385	87.2%	89.1%	92.1%	87.2%	89.1%	88.1%


	Beneficiaries With Hypertension and Any Antihypertensive Medication Use					
	White	Black	Asian	Hispanic	American Indian/Alaska Native	Other Race
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
386	85.7%	87.4%	87.1%	76.7%	72.8%	88.9%
388	85.8%	88.9%	93.2%	84.1%	*	91.8%
390	85.2%	87.1%	78.4%	83.1%	*	82.3%
391	86.4%	88.6%	88.2%	86.0%	80.7%	84.1%
393	83.8%	85.2%	81.9%	84.4%	72.6%	80.3%
394	87.3%	88.2%	90.3%	86.9%	78.8%	86.1%
396	84.3%	83.3%	85.0%	83.9%	*	79.2%
397	87.3%	88.0%	90.1%	86.0%	85.8%	86.3%
399	86.5%	90.3%	86.4%	86.8%	86.3%	79.2%
400	87.6%	88.7%	80.6%	86.2%	91.0%	87.8%
402	83.3%	87.9%	88.9%	82.2%	*	81.8%
406	86.7%	90.4%	82.9%	86.6%	71.1%	83.9%
411	86.6%	89.9%	93.0%	84.8%	80.6%	88.7%
412	85.2%	86.6%	89.6%	83.6%	85.9%	83.8%
413	84.9%	87.1%	82.9%	83.3%	80.7%	86.8%
416	87.1%	89.2%	83.7%	85.5%	86.1%	86.1%
417	87.8%	90.5%	90.0%	85.7%	*	83.5%
418	87.7%	89.9%	94.1%	89.0%	80.2%	89.9%
420	87.9%	89.4%	92.9%	85.7%	86.4%	79.3%
421	87.2%	92.6%	82.3%	86.0%	83.3%	85.5%
422	88.6%	82.4%	82.5%	89.3%	81.3%	86.5%
423	88.7%	89.1%	87.2%	88.1%	87.1%	88.7%
424	89.1%	88.8%	87.5%	85.8%	87.9%	81.5%
426	88.0%	88.2%	88.2%	86.7%	89.1%	86.1%
427	88.8%	91.9%	86.9%	83.5%	*	89.8%
428	89.5%	91.2%	94.7%	*	*	82.6%
429	87.9%	89.7%	90.3%	85.6%	79.3%	85.4%
430	87.2%	89.2%	87.2%	81.9%	74.0%	86.5%
431	88.3%	89.0%	88.3%	80.8%	86.1%	89.0%
432	88.4%	89.7%	84.6%	88.3%	91.0%	86.6%
435	89.0%	89.9%	95.4%	84.4%	*	89.1%
437	89.7%	91.4%	93.3%	89.1%	88.4%	89.7%
438	87.5%	84.1%	89.4%	87.2%	85.0%	85.5%
439	89.5%	92.0%	92.6%	88.8%	85.4%	89.9%
440	88.6%	91.2%	88.4%	89.5%	85.5%	90.8%
441	89.2%	91.1%	91.9%	91.2%	92.7%	87.6%
442	89.0%	89.4%	84.1%	87.5%	90.1%	93.1%

	Beneficiaries With Hypertension and Any Antihypertensive Medication Use					
	White	Black	Asian	Hispanic	American Indian/Alaska Native	Other Race
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
443	88.9%	87.3%	72.9%	87.9%	89.2%	82.7%
444	88.9%	86.9%	92.6%	*	*	82.9%
445	88.1%	93.9%	86.9%	*	*	86.1%
446	90.1%	87.3%	90.3%	100.0%	79.6%	95.2%
447	90.9%	94.4%	86.7%	87.4%	84.0%	88.9%
448	92.7%	95.7%	92.8%	*	75.0%	90.8%
449	92.3%	93.4%	95.5%	94.5%	63.6%	90.1%
450	92.3%	100.0%	91.8%	94.3%	82.6%	93.8%
451	89.8%	90.8%	87.8%	88.0%	87.0%	88.6%
452	91.7%	88.2%	94.1%	77.1%	*	100.0%
456	92.0%	*	86.9%	*	84.6%	91.1%
457	91.5%	87.2%	*	89.7%	79.7%	88.7%


Table 6. Dartmouth Atlas of Health Care Maps of the Proportion of Medicare Parts A, B, and D Beneficiaries With Hypertension and Use of One or More Antihypertensive Drugs, by HRR and Race; Adjusted by Age Category, Gender, and Comorbid Conditions, 2009




Proportion (%) of Hypertensive Beneficiaries with Antihypertensive Drug Use, 2009
Race = Black




Proportion (%) of Hypertensive Beneficiaries with Antihypertensive Drug Use, 2009
Race = Asian



Proportion (%) of Hypertensive Beneficiaries with Antihypertensive Drug Use, 2009
Race = Hispanic



Proportion (%) of Hypertensive Beneficiaries with Antihypertensive Drug Use, 2009
Race = Native American



Note: Native American includes American Indians and Alaska Natives.

Proportion (%) of Hypertensive Beneficiaries with Antihypertensive Drug Use, 2009
Race = Other




Table 7. Proportion of Medicare Parts A, B, and D Beneficiaries With Hypertension and Use of One or More Antihypertensive Drugs, by Drug Class and HRR; Adjusted by Age Category, Gender, Race, and Comorbid Conditions, 2009

Note: An asterisk (*) indicates a small cell count (<11).

	Antihypertensive Medication Utilization by Medicare Beneficiaries								
	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin-Angiotensin System Antagonists	Combined Therapy
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
1	30.0%	13.2%	27.7%	33.8%	40.3%	9.2%	2.5%	0.5%	27.6%
2	30.8%	12.7%	30.1%	39.1%	42.5%	12.0%	2.8%	0.6%	26.4%
5	32.8%	12.4%	29.6%	38.7%	42.0%	8.7%	1.8%	0.5%	27.7%
6	27.9%	11.5%	29.0%	36.6%	41.6%	10.0%	3.1%	0.6%	28.6%
7	29.7%	12.1%	29.4%	36.5%	41.0%	11.0%	3.2%	0.6%	26.2%
9	32.9%	11.1%	26.9%	41.9%	38.4%	10.8%	2.0%	0.2%	25.8%
10	37.7%	18.1%	29.1%	41.0%	46.4%	7.6%	1.4%	0.9%	22.3%
11	35.3%	14.9%	30.1%	31.9%	43.6%	8.5%	2.6%	0.4%	22.9%
12	37.2%	13.3%	30.9%	32.9%	43.2%	8.7%	2.5%	0.5%	20.3%
14	32.8%	15.4%	31.5%	28.8%	43.6%	9.3%	4.0%	0.5%	18.9%
15	36.5%	14.7%	31.2%	34.8%	42.1%	10.1%	2.3%	0.8%	19.5%
16	30.2%	11.5%	30.8%	38.8%	43.9%	9.6%	1.0%	0.5%	25.2%
18	31.5%	11.4%	33.3%	40.9%	38.8%	10.9%	1.9%	0.6%	29.7%
19	28.5%	11.1%	29.8%	35.9%	42.9%	9.9%	1.6%	0.5%	30.3%
21	30.3%	12.3%	29.0%	35.4%	43.1%	9.6%	1.6%	0.5%	26.1%
22	29.5%	10.7%	26.9%	37.2%	41.1%	10.8%	1.9%	0.4%	28.0%
23	30.9%	18.2%	30.2%	27.4%	40.4%	10.9%	1.9%	1.3%	23.5%
25	36.8%	17.0%	28.4%	34.2%	38.8%	8.3%	1.3%	1.0%	20.4%
31	36.7%	16.0%	29.8%	38.0%	40.9%	8.1%	1.4%	0.7%	20.2%
33	35.6%	16.7%	30.5%	35.9%	44.9%	8.5%	2.1%	0.6%	18.0%
43	35.2%	15.5%	28.2%	34.2%	43.3%	6.8%	2.0%	0.8%	25.7%
56	27.7%	20.3%	30.7%	26.9%	38.0%	9.3%	1.9%	1.4%	24.9%
58	40.0%	15.5%	29.5%	38.4%	43.4%	8.7%	1.5%	0.5%	19.6%
62	38.0%	15.2%	30.2%	37.3%	41.6%	7.3%	1.3%	0.4%	19.8%
65	34.0%	16.9%	31.7%	36.6%	43.3%	8.7%	2.7%	0.4%	16.2%
69	31.9%	18.0%	29.1%	30.1%	37.5%	7.5%	1.4%	1.0%	21.5%
73	36.7%	14.6%	29.9%	38.2%	40.8%	8.4%	1.3%	0.3%	22.0%
77	37.9%	15.9%	31.5%	36.4%	41.4%	8.3%	2.8%	0.6%	20.5%
78	33.1%	16.4%	28.9%	32.6%	38.9%	8.4%	3.5%	0.6%	23.6%
79	35.9%	15.2%	30.9%	33.2%	39.8%	9.5%	1.5%	0.6%	20.2%

	Antihypertensive Medication Utilization by Medicare Beneficiaries								
	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin-Angiotensin System Antagonists	Combined Therapy
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
80	33.4%	18.6%	31.7%	33.9%	41.4%	8.1%	2.0%	1.2%	21.1%
81	35.1%	18.1%	33.2%	37.8%	46.3%	8.0%	2.6%	0.6%	16.2%
82	33.3%	20.1%	34.9%	34.2%	44.2%	8.3%	2.2%	1.0%	22.2%
83	36.1%	17.4%	30.6%	33.4%	42.2%	7.9%	1.2%	0.4%	19.4%
85	32.0%	19.2%	32.7%	34.9%	40.9%	7.4%	2.4%	0.7%	20.0%
86	33.3%	17.2%	29.0%	32.8%	34.8%	8.8%	2.7%	0.7%	21.8%
87	37.0%	16.2%	30.8%	35.6%	37.9%	9.0%	2.0%	0.3%	17.9%
89	37.5%	15.4%	28.9%	36.9%	38.5%	7.1%	1.2%	0.8%	20.1%
91	40.6%	15.6%	31.2%	37.2%	43.8%	6.7%	2.2%	0.7%	19.8%
96	32.0%	17.4%	29.1%	30.8%	37.8%	9.2%	2.8%	0.9%	23.1%
101	35.5%	15.4%	29.6%	35.9%	39.6%	6.5%	2.4%	*	21.8%
102	34.6%	11.8%	28.9%	36.7%	41.1%	9.9%	1.8%	0.4%	20.7%
103	36.4%	14.1%	28.7%	37.8%	43.3%	8.2%	2.3%	0.5%	22.9%
104	38.0%	14.1%	28.6%	39.3%	44.8%	7.5%	2.7%	0.4%	23.0%
105	36.8%	12.5%	27.4%	39.3%	46.9%	8.0%	1.3%	0.2%	22.2%
106	38.8%	12.2%	26.8%	41.7%	44.7%	10.0%	2.1%	0.3%	22.3%
107	35.9%	11.7%	29.7%	37.1%	39.6%	8.2%	2.0%	0.3%	18.2%
109	29.5%	15.9%	28.3%	32.8%	43.4%	4.3%	1.3%	0.5%	21.2%
110	33.4%	13.6%	29.0%	37.4%	48.5%	5.3%	1.6%	0.6%	19.1%
111	32.3%	14.1%	30.3%	36.5%	47.0%	5.1%	1.6%	0.5%	18.5%
112	29.8%	12.9%	27.3%	34.1%	40.9%	6.3%	2.1%	0.5%	23.2%
113	32.4%	15.2%	30.0%	33.8%	42.3%	7.3%	2.4%	0.5%	22.9%
115	25.7%	12.2%	26.2%	28.9%	37.8%	8.0%	1.9%	0.7%	25.1%
116	32.4%	13.0%	29.5%	31.6%	42.8%	8.5%	1.5%	0.5%	20.7%
118	26.6%	15.6%	29.7%	28.2%	40.3%	8.1%	1.7%	0.7%	21.9%
119	29.5%	14.1%	29.3%	31.1%	43.0%	6.4%	1.7%	0.8%	23.9%
120	34.3%	12.4%	33.2%	37.0%	41.5%	8.9%	1.7%	0.4%	20.8%
122	31.2%	10.9%	27.4%	30.6%	43.3%	9.8%	1.1%	0.4%	20.2%
123	34.1%	13.6%	31.7%	35.8%	43.1%	9.5%	2.7%	0.5%	21.8%
124	30.9%	12.2%	30.5%	32.1%	42.8%	9.4%	1.8%	0.6%	21.7%
127	28.6%	16.4%	28.8%	26.9%	40.6%	9.1%	1.4%	1.0%	26.2%
129	32.6%	12.3%	27.9%	31.1%	42.7%	8.0%	1.7%	0.6%	22.4%
130	29.9%	12.6%	30.2%	30.5%	42.1%	9.2%	2.4%	0.5%	23.2%

	Antihypertensive Medication Utilization by Medicare Beneficiaries								
	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin-Angiotensin System Antagonists	Combined Therapy
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
131	30.8%	13.0%	29.6%	31.5%	40.2%	8.5%	1.4%	0.5%	21.0%
133	32.8%	16.6%	28.0%	33.5%	49.1%	9.0%	1.0%	1.0%	24.6%
134	32.1%	12.2%	28.1%	36.9%	42.2%	13.0%	1.9%	0.8%	25.2%
137	29.4%	14.8%	27.6%	29.5%	43.1%	6.6%	0.9%	0.7%	24.6%
139	33.2%	14.5%	29.6%	31.7%	40.3%	7.8%	1.8%	0.7%	19.8%
140	29.8%	13.6%	28.2%	35.6%	41.9%	8.9%	2.0%	0.8%	26.0%
141	32.2%	14.0%	31.2%	30.8%	40.0%	8.9%	2.2%	0.7%	25.0%
142	31.2%	13.1%	29.9%	38.8%	40.0%	10.3%	4.7%	0.5%	25.8%
144	32.0%	13.2%	32.4%	34.6%	43.5%	9.4%	3.5%	0.5%	26.0%
145	29.2%	14.1%	30.0%	35.1%	40.6%	8.5%	2.7%	0.9%	30.3%
146	31.4%	11.3%	31.3%	37.5%	38.7%	10.2%	2.1%	0.6%	25.0%
147	29.9%	13.8%	29.5%	34.8%	42.5%	8.9%	2.5%	0.8%	27.9%
148	32.4%	9.6%	30.9%	37.3%	41.7%	9.2%	2.8%	0.6%	29.7%
149	29.1%	13.8%	28.8%	35.5%	40.1%	7.5%	2.1%	0.7%	29.3%
150	27.3%	19.3%	27.6%	29.1%	35.1%	5.6%	2.1%	0.7%	21.2%
151	37.6%	15.3%	32.4%	41.3%	43.7%	8.7%	1.3%	0.7%	22.7%
152	31.6%	13.2%	26.7%	37.0%	40.0%	9.1%	1.1%	0.4%	28.6%
154	35.7%	13.3%	29.7%	37.1%	47.9%	8.2%	2.0%	0.3%	22.4%
155	31.9%	11.2%	29.8%	32.8%	45.0%	7.0%	2.9%	0.4%	23.7%
156	34.2%	12.9%	29.7%	35.3%	43.2%	6.3%	2.7%	0.3%	20.6%
158	31.6%	12.1%	32.0%	33.5%	49.5%	7.1%	3.0%	0.4%	24.4%
161	33.1%	14.1%	30.2%	34.6%	46.6%	6.6%	2.4%	0.7%	22.3%
163	33.7%	13.5%	30.3%	33.6%	44.6%	6.8%	3.1%	0.5%	25.9%
164	30.6%	12.3%	30.2%	35.2%	43.2%	8.0%	2.4%	0.5%	26.1%
166	33.4%	12.4%	30.3%	34.6%	45.6%	6.5%	2.9%	0.4%	24.3%
170	37.0%	12.0%	28.4%	41.0%	46.8%	7.1%	2.3%	0.5%	23.2%
171	37.7%	11.7%	31.7%	40.6%	50.1%	8.6%	3.7%	0.3%	20.6%
172	35.9%	12.2%	30.7%	41.4%	51.8%	7.7%	1.9%	0.5%	21.7%
173	34.3%	12.1%	28.1%	40.5%	48.1%	7.7%	1.5%	0.4%	25.1%
175	34.4%	13.2%	29.5%	37.9%	47.8%	7.1%	1.6%	0.8%	23.8%
179	33.3%	13.0%	30.6%	40.8%	44.1%	10.0%	2.3%	0.8%	24.6%
180	29.1%	13.1%	32.2%	36.4%	46.8%	7.9%	2.2%	0.4%	27.5%
181	31.9%	12.8%	29.2%	34.5%	42.3%	7.1%	2.1%	0.7%	27.7%

	Antihypertensive Medication Utilization by Medicare Beneficiaries								
	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin-Angiotensin System Antagonists	Combined Therapy
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
183	33.1%	13.1%	32.4%	37.0%	47.0%	9.0%	2.6%	0.6%	26.8%
184	34.6%	11.8%	34.1%	39.6%	47.1%	9.2%	3.1%	0.2%	23.9%
185	33.4%	11.1%	32.0%	41.0%	45.3%	8.0%	3.4%	1.0%	26.1%
186	30.8%	12.0%	29.1%	33.6%	42.0%	7.5%	2.6%	0.3%	25.2%
187	33.4%	12.6%	29.7%	38.7%	43.5%	7.9%	1.9%	0.5%	23.6%
188	31.5%	11.1%	30.7%	39.1%	51.1%	7.4%	2.4%	0.6%	27.4%
190	36.4%	10.7%	30.9%	44.3%	55.4%	7.1%	1.3%	0.2%	22.5%
191	34.9%	11.4%	27.9%	39.1%	47.5%	6.7%	2.0%	0.3%	23.1%
192	33.5%	11.5%	30.9%	40.0%	47.6%	8.8%	1.9%	0.4%	26.3%
193	37.2%	11.2%	30.7%	42.1%	51.3%	6.7%	1.4%	*	20.0%
194	37.5%	10.5%	29.4%	45.7%	50.8%	7.5%	1.9%	0.2%	18.5%
195	38.3%	11.1%	27.3%	44.5%	50.1%	5.9%	2.8%	0.3%	24.5%
196	35.9%	12.3%	35.2%	43.8%	45.8%	7.9%	1.4%	0.6%	25.4%
197	36.0%	10.2%	33.0%	44.9%	52.9%	6.7%	3.7%	0.3%	21.6%
200	33.6%	14.3%	28.9%	40.5%	43.6%	8.6%	1.1%	0.8%	22.1%
201	32.2%	12.1%	31.2%	40.5%	42.7%	8.4%	1.6%	0.6%	26.7%
203	36.1%	11.6%	31.4%	37.8%	44.8%	9.0%	3.2%	0.6%	23.6%
204	36.9%	12.4%	31.5%	41.7%	48.2%	8.6%	2.5%	1.1%	23.6%
205	32.1%	11.2%	31.0%	38.7%	46.3%	7.8%	3.7%	0.7%	26.3%
207	34.9%	14.7%	30.8%	38.7%	40.6%	7.6%	2.2%	0.8%	22.0%
208	36.6%	14.0%	28.4%	39.9%	43.2%	10.0%	1.7%	0.9%	24.0%
209	27.2%	14.0%	30.5%	38.6%	40.9%	10.1%	1.5%	1.0%	28.0%
210	27.3%	14.7%	29.6%	37.9%	42.4%	10.4%	2.6%	0.7%	27.2%
212	29.7%	13.8%	29.4%	35.4%	49.3%	10.1%	1.5%	1.0%	28.9%
213	27.9%	13.0%	27.8%	34.7%	39.7%	10.1%	1.9%	0.8%	32.5%
214	30.9%	11.9%	29.3%	37.3%	42.9%	10.4%	1.9%	0.6%	27.7%
216	32.4%	13.9%	29.3%	37.7%	44.3%	9.4%	1.8%	0.7%	25.8%
217	29.2%	13.6%	28.9%	37.7%	41.2%	12.3%	1.8%	0.7%	31.1%
218	31.8%	15.7%	30.5%	36.6%	42.4%	8.4%	2.2%	0.8%	25.0%
219	30.0%	13.1%	29.1%	36.2%	41.9%	10.2%	2.4%	0.5%	24.2%
220	31.3%	13.8%	29.4%	35.0%	42.1%	9.8%	1.8%	0.6%	28.7%
221	38.4%	11.8%	27.8%	43.4%	51.1%	8.6%	1.9%	0.3%	13.5%
222	36.5%	12.6%	28.3%	43.3%	51.2%	6.9%	2.3%	0.2%	13.1%

	Antihypertensive Medication Utilization by Medicare Beneficiaries								
	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin-Angiotensin System Antagonists	Combined Therapy
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
223	30.4%	13.3%	30.2%	33.0%	45.0%	6.2%	2.1%	0.6%	23.1%
225	29.3%	14.1%	28.0%	36.8%	45.2%	7.3%	2.1%	0.4%	22.2%
226	29.3%	15.7%	30.5%	30.3%	40.6%	7.4%	2.1%	0.5%	26.3%
227	39.7%	12.3%	31.4%	41.5%	51.7%	7.2%	1.6%	0.2%	12.6%
230	39.1%	13.4%	31.9%	41.6%	48.4%	7.4%	1.5%	0.3%	14.7%
231	39.3%	10.6%	28.3%	41.8%	49.7%	6.9%	1.4%	0.2%	11.0%
232	35.2%	10.0%	28.9%	34.1%	45.6%	7.5%	2.7%	0.3%	21.8%
233	34.3%	8.8%	27.4%	30.5%	44.3%	8.0%	3.0%	0.4%	23.4%
234	35.7%	9.3%	29.8%	32.7%	43.8%	7.5%	3.1%	0.4%	22.5%
235	34.9%	8.7%	28.8%	33.2%	42.8%	8.5%	2.3%	0.3%	20.9%
236	36.2%	10.5%	29.5%	37.7%	47.6%	7.7%	3.6%	0.4%	23.2%
238	34.5%	10.4%	29.1%	39.3%	47.2%	8.4%	3.3%	0.2%	24.8%
239	35.0%	10.0%	30.7%	37.6%	43.2%	8.1%	1.7%	0.3%	21.8%
240	36.5%	11.8%	30.6%	41.6%	45.3%	6.7%	1.3%	0.5%	21.1%
242	35.7%	9.2%	28.6%	36.8%	46.4%	7.5%	1.5%	0.3%	22.5%
243	31.8%	11.2%	26.9%	36.4%	46.3%	7.0%	1.7%	0.3%	22.4%
244	32.2%	10.3%	29.2%	30.5%	39.2%	6.8%	2.7%	0.5%	22.8%
245	30.1%	11.8%	27.1%	28.5%	42.8%	6.3%	2.9%	0.8%	24.1%
246	34.1%	9.4%	28.7%	36.7%	44.5%	7.4%	2.0%	0.4%	22.1%
248	30.8%	14.0%	30.7%	35.0%	42.1%	8.4%	2.2%	0.3%	27.1%
249	34.1%	11.0%	29.1%	36.1%	43.6%	7.6%	1.5%	0.6%	23.5%
250	41.1%	15.6%	31.2%	48.8%	55.4%	7.2%	1.2%	0.2%	15.0%
251	37.9%	13.1%	30.7%	43.6%	56.4%	7.4%	2.7%	0.2%	21.4%
253	39.9%	12.8%	30.3%	47.9%	57.5%	6.6%	1.8%	0.2%	19.7%
254	40.2%	13.3%	29.4%	43.4%	52.9%	8.5%	1.9%	0.2%	21.2%
256	39.1%	14.0%	31.3%	43.9%	52.8%	8.7%	3.2%	0.1%	19.8%
257	30.3%	14.1%	31.3%	35.4%	38.7%	8.7%	2.0%	0.8%	28.8%
258	27.4%	14.9%	29.3%	37.1%	40.6%	9.1%	2.8%	0.6%	34.0%
259	26.5%	12.1%	27.8%	37.9%	39.3%	8.8%	2.2%	0.4%	33.5%
260	26.2%	9.7%	30.6%	40.1%	40.8%	9.8%	2.6%	0.3%	29.8%
261	27.3%	12.8%	27.1%	39.4%	42.3%	11.0%	2.9%	0.4%	34.9%
262	30.6%	12.3%	27.0%	39.0%	43.0%	9.5%	2.0%	0.5%	31.0%
263	33.8%	12.7%	30.1%	39.8%	45.1%	8.1%	3.5%	0.9%	26.7%

	Antihypertensive Medication Utilization by Medicare Beneficiaries								
	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin-Angiotensin System Antagonists	Combined Therapy
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
264	34.2%	11.3%	30.9%	39.6%	44.4%	7.6%	1.4%	0.3%	22.1%
267	32.2%	12.5%	31.3%	38.4%	44.1%	10.3%	1.8%	0.7%	24.0%
268	35.1%	12.8%	31.8%	37.4%	43.4%	9.4%	2.1%	0.5%	22.3%
270	35.5%	13.0%	33.3%	38.6%	44.8%	9.9%	2.0%	0.8%	20.9%
273	35.2%	12.8%	32.1%	38.0%	45.5%	7.7%	3.2%	0.5%	21.9%
274	35.4%	14.8%	28.0%	41.4%	45.8%	8.3%	0.9%	0.6%	26.4%
275	33.4%	17.2%	28.3%	40.9%	43.6%	7.1%	1.2%	0.5%	25.8%
276	38.2%	15.1%	28.9%	42.9%	46.4%	8.4%	0.9%	0.3%	20.2%
277	33.4%	13.2%	29.9%	37.2%	48.4%	8.3%	1.7%	0.7%	26.3%
278	34.5%	12.3%	31.5%	39.0%	51.5%	9.3%	2.3%	0.5%	26.0%
279	32.8%	13.0%	30.7%	29.9%	38.4%	8.5%	3.3%	0.7%	22.2%
280	37.1%	14.2%	29.9%	37.8%	41.6%	8.6%	1.3%	0.5%	20.7%
281	38.1%	13.7%	29.9%	45.2%	54.2%	6.5%	1.0%	0.1%	13.2%
282	35.5%	12.9%	30.3%	39.3%	49.8%	6.6%	1.2%	0.3%	15.1%
283	28.1%	14.9%	30.0%	31.7%	43.2%	6.5%	2.0%	0.7%	22.1%
284	25.3%	16.9%	28.7%	28.8%	42.6%	5.8%	1.1%	1.2%	25.8%
285	27.1%	15.5%	29.6%	30.6%	42.6%	6.6%	1.1%	0.9%	26.2%
288	27.6%	15.2%	30.6%	30.5%	43.1%	7.7%	1.4%	0.7%	23.2%
289	24.2%	16.3%	27.9%	28.2%	39.0%	5.7%	1.3%	1.1%	28.8%
291	27.3%	14.8%	28.8%	31.8%	41.0%	7.0%	1.5%	0.7%	25.1%
292	27.3%	16.2%	28.9%	30.9%	42.2%	5.7%	1.1%	0.9%	23.5%
293	37.3%	13.0%	29.1%	36.8%	41.2%	9.0%	1.8%	0.3%	18.8%
295	34.0%	13.1%	29.2%	39.1%	47.7%	6.3%	1.8%	0.4%	17.7%
296	35.1%	14.9%	30.0%	40.9%	48.3%	5.7%	1.0%	0.8%	21.8%
297	33.3%	13.9%	33.3%	32.6%	44.1%	5.8%	1.9%	0.5%	19.3%
299	35.0%	12.3%	30.6%	37.8%	46.1%	8.3%	2.7%	0.5%	19.5%
300	35.2%	15.1%	28.6%	37.9%	48.2%	6.9%	2.5%	0.5%	19.1%
301	27.8%	15.3%	28.7%	27.5%	43.9%	5.8%	1.8%	0.6%	21.5%
303	28.0%	17.7%	30.9%	29.3%	44.6%	6.5%	1.6%	1.1%	24.2%
304	36.9%	12.4%	30.5%	40.3%	49.8%	5.9%	2.3%	0.4%	16.2%
307	33.7%	14.5%	29.3%	39.4%	46.7%	6.7%	1.1%	0.5%	19.1%
308	29.4%	15.1%	28.9%	31.0%	44.5%	5.1%	1.0%	0.6%	19.8%
309	34.4%	13.9%	30.6%	42.0%	44.8%	8.7%	1.1%	0.5%	23.4%


	Antihypertensive Medication Utilization by Medicare Beneficiaries								
	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin-Angiotensin System Antagonists	Combined Therapy
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
311	31.1%	12.7%	31.5%	36.9%	41.5%	8.6%	2.1%	0.7%	27.8%
312	33.5%	12.9%	30.3%	39.2%	45.3%	7.6%	2.4%	0.5%	25.0%
313	29.7%	13.2%	31.5%	39.6%	44.7%	8.0%	2.0%	0.7%	25.2%
314	30.6%	13.5%	29.6%	40.5%	43.5%	7.5%	2.7%	0.7%	28.1%
315	32.0%	12.4%	32.5%	39.3%	39.4%	8.6%	2.0%	0.6%	28.2%
318	29.1%	12.9%	29.4%	38.2%	44.4%	7.2%	2.4%	0.8%	28.9%
319	27.8%	13.5%	28.0%	37.6%	41.9%	7.9%	2.4%	1.1%	29.8%
320	33.1%	12.4%	29.6%	41.3%	46.0%	7.5%	2.4%	0.4%	23.5%
321	36.9%	14.2%	31.0%	44.8%	49.3%	8.3%	1.0%	0.2%	25.8%
322	37.8%	12.8%	31.6%	43.3%	51.7%	7.4%	2.2%	0.3%	25.9%
323	43.4%	13.1%	32.1%	45.4%	50.2%	6.1%	1.4%	0.2%	20.8%
324	40.5%	12.8%	27.5%	48.4%	51.3%	8.2%	1.3%	*	23.2%
325	35.7%	11.4%	29.2%	37.9%	40.1%	8.1%	2.9%	0.5%	20.3%
326	34.6%	13.4%	28.8%	40.8%	46.9%	8.0%	2.3%	0.9%	21.4%
327	33.9%	12.1%	31.7%	38.1%	42.9%	8.8%	2.1%	0.7%	23.3%
328	34.2%	12.4%	30.4%	37.7%	47.5%	7.9%	2.9%	0.4%	21.0%
329	33.7%	12.3%	30.1%	38.1%	47.9%	8.2%	2.2%	0.6%	24.4%
330	31.2%	11.5%	30.2%	36.6%	45.6%	9.1%	3.0%	0.6%	23.6%
331	30.6%	11.7%	31.4%	35.2%	46.4%	6.8%	2.7%	0.6%	26.2%
332	31.8%	12.5%	30.0%	36.8%	45.1%	8.9%	2.5%	0.4%	24.3%
334	31.6%	9.3%	27.9%	34.3%	45.1%	7.3%	2.3%	0.3%	22.4%
335	29.1%	11.8%	29.5%	33.9%	42.9%	8.6%	3.3%	0.6%	20.6%
336	31.4%	11.9%	26.7%	36.6%	43.9%	12.0%	2.8%	0.4%	29.3%
339	30.5%	11.6%	28.3%	37.8%	40.0%	11.6%	1.9%	0.7%	26.8%
340	32.8%	12.5%	29.9%	38.3%	44.5%	11.8%	2.1%	0.8%	25.0%
341	39.1%	13.9%	30.8%	40.1%	43.0%	8.7%	1.5%	*	20.3%
342	37.5%	14.5%	29.2%	42.2%	49.0%	9.0%	1.3%	0.4%	19.1%
343	35.3%	13.7%	28.3%	39.6%	47.1%	7.8%	2.0%	0.5%	19.4%
344	40.1%	15.0%	30.3%	42.8%	48.4%	8.9%	1.8%	0.2%	19.2%
345	38.1%	14.5%	32.8%	44.7%	49.1%	8.8%	2.5%	*	17.5%
346	30.2%	13.7%	30.1%	34.5%	45.3%	6.1%	0.9%	0.7%	22.9%
347	33.5%	14.2%	27.4%	38.5%	47.1%	6.1%	1.2%	0.3%	19.6%
350	32.4%	11.4%	28.2%	38.3%	50.1%	6.4%	1.6%	0.5%	20.9%

	Antihypertensive Medication Utilization by Medicare Beneficiaries								
	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin-Angiotensin System Antagonists	Combined Therapy
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
351	31.2%	12.9%	28.5%	38.3%	47.2%	7.1%	2.6%	0.3%	19.9%
352	33.8%	13.8%	30.8%	39.0%	46.9%	7.4%	2.9%	0.3%	19.9%
354	27.8%	13.6%	28.2%	38.0%	47.8%	6.4%	1.6%	0.6%	23.7%
355	33.0%	12.8%	27.9%	38.8%	47.0%	7.4%	1.5%	0.5%	21.0%
356	30.5%	14.0%	30.0%	32.6%	43.6%	6.3%	2.1%	0.5%	20.3%
357	30.6%	13.3%	28.9%	34.7%	43.3%	6.8%	1.8%	0.4%	21.4%
358	31.6%	12.0%	27.1%	33.7%	48.6%	5.2%	2.8%	0.7%	23.5%
359	36.9%	13.5%	26.8%	40.6%	49.8%	6.7%	1.6%	0.6%	21.5%
360	29.7%	13.7%	27.6%	34.0%	45.0%	7.5%	0.8%	0.9%	23.7%
362	26.8%	12.9%	27.1%	35.5%	46.7%	6.9%	0.8%	0.5%	22.3%
363	33.2%	11.9%	30.2%	39.9%	47.0%	7.3%	3.5%	0.3%	19.7%
364	36.6%	13.6%	31.9%	37.5%	47.8%	6.4%	1.7%	0.4%	16.6%
365	27.6%	13.8%	29.6%	34.0%	39.4%	7.0%	2.2%	0.9%	28.7%
366	26.6%	14.3%	29.0%	35.4%	40.0%	7.6%	1.6%	0.9%	30.4%
367	29.9%	13.6%	28.0%	37.9%	42.9%	8.9%	1.7%	0.9%	32.6%
368	31.0%	12.8%	28.2%	35.6%	40.6%	6.6%	1.9%	0.7%	27.4%
369	28.4%	11.7%	33.7%	35.7%	42.1%	8.6%	2.3%	0.7%	29.6%
370	37.2%	15.7%	32.2%	40.3%	45.6%	7.4%	1.2%	0.4%	23.9%
371	35.9%	12.9%	32.6%	41.8%	51.0%	7.5%	2.2%	0.5%	24.5%
373	32.2%	13.0%	29.4%	37.0%	39.9%	9.6%	2.0%	0.8%	27.6%
374	32.6%	11.9%	31.4%	40.6%	39.5%	10.9%	2.5%	0.5%	27.6%
375	36.4%	12.4%	32.0%	40.6%	43.3%	10.1%	1.9%	0.5%	24.6%
376	36.3%	12.5%	29.6%	42.7%	47.0%	8.8%	1.6%	0.6%	25.4%
377	35.1%	12.1%	31.6%	40.0%	44.0%	11.3%	3.7%	0.6%	25.2%
379	30.9%	11.7%	31.4%	37.4%	40.0%	10.7%	3.3%	0.4%	30.4%
380	36.1%	12.6%	31.9%	40.0%	42.2%	9.4%	2.9%	0.6%	25.3%
382	30.2%	10.8%	26.7%	34.6%	43.5%	11.4%	1.6%	0.3%	26.9%
383	32.0%	12.9%	28.7%	36.1%	45.1%	10.6%	2.1%	0.6%	28.6%
385	31.6%	13.3%	32.0%	33.6%	40.2%	9.8%	2.6%	0.7%	23.3%
386	28.8%	11.6%	26.6%	33.8%	41.5%	9.3%	2.2%	0.6%	28.9%
388	28.5%	10.6%	30.0%	33.9%	40.7%	10.3%	3.2%	0.3%	24.7%
390	27.3%	12.0%	29.1%	30.7%	35.4%	9.0%	2.3%	0.6%	27.3%
391	31.1%	12.6%	29.9%	33.8%	40.6%	9.7%	2.3%	0.6%	26.3%


	Antihypertensive Medication Utilization by Medicare Beneficiaries								
	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin-Angiotensin System Antagonists	Combined Therapy
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
393	32.4%	14.2%	28.1%	29.5%	38.4%	7.8%	2.3%	0.6%	25.2%
394	31.9%	11.6%	31.7%	34.1%	43.1%	10.7%	2.3%	0.5%	25.3%
396	26.6%	13.1%	28.9%	26.9%	35.5%	7.8%	3.7%	0.7%	26.7%
397	30.8%	13.2%	30.3%	32.1%	42.2%	10.2%	2.4%	0.7%	26.6%
399	29.1%	11.4%	29.2%	36.8%	41.6%	10.1%	2.1%	0.6%	27.0%
400	34.0%	10.4%	29.0%	36.7%	42.2%	9.3%	1.8%	0.4%	26.5%
402	22.7%	13.8%	27.2%	26.3%	35.7%	7.8%	2.3%	0.5%	30.3%
406	31.6%	12.1%	27.6%	30.5%	41.3%	8.5%	2.0%	1.0%	30.8%
411	31.1%	11.5%	25.8%	35.7%	45.5%	8.5%	1.6%	0.4%	25.9%
412	30.8%	13.9%	29.4%	30.4%	37.5%	7.7%	2.3%	0.7%	24.1%
413	30.2%	11.4%	27.0%	37.1%	45.3%	8.7%	2.2%	0.4%	19.7%
416	30.6%	12.7%	30.4%	35.2%	41.3%	9.6%	1.4%	0.6%	26.1%
417	27.9%	17.0%	28.2%	33.6%	41.6%	10.7%	2.5%	1.0%	27.8%
418	30.0%	10.3%	30.3%	37.9%	42.4%	9.6%	1.0%	0.4%	25.6%
420	34.2%	11.7%	30.0%	36.7%	40.6%	10.3%	0.9%	0.3%	27.5%
421	36.2%	14.5%	27.9%	38.4%	38.4%	8.9%	1.2%	1.2%	25.4%
422	30.8%	11.8%	25.5%	36.8%	38.2%	6.8%	0.8%	1.0%	33.1%
423	36.2%	14.0%	27.9%	38.8%	38.9%	7.8%	1.6%	0.7%	27.5%
424	36.5%	15.5%	29.0%	42.3%	49.1%	5.9%	1.0%	0.2%	16.4%
426	31.2%	16.4%	31.4%	31.6%	43.7%	7.1%	1.9%	0.9%	25.7%
427	35.5%	13.7%	28.1%	45.1%	44.9%	8.0%	1.3%	0.3%	20.2%
428	35.6%	12.0%	25.7%	43.5%	47.3%	7.0%	2.4%	0.4%	21.2%
429	30.0%	14.7%	30.3%	36.9%	41.9%	8.9%	2.5%	0.9%	25.2%
430	29.3%	13.8%	29.4%	37.7%	42.9%	8.1%	2.8%	0.5%	22.9%
431	30.7%	14.1%	30.6%	39.1%	42.0%	8.7%	2.1%	0.6%	22.6%
432	30.9%	12.4%	29.8%	40.8%	43.1%	8.7%	2.0%	0.3%	23.5%
435	32.8%	14.0%	31.6%	39.7%	45.6%	8.6%	1.8%	0.4%	24.6%
437	42.8%	14.7%	29.5%	44.6%	50.7%	8.1%	1.8%	0.2%	15.1%
438	38.8%	14.3%	27.8%	43.4%	44.7%	6.9%	2.3%	0.2%	17.9%
439	40.7%	15.3%	31.9%	43.2%	48.0%	7.6%	1.7%	0.3%	17.3%
440	39.0%	14.8%	31.3%	43.5%	41.6%	8.2%	1.2%	0.3%	18.1%
441	38.0%	15.8%	33.2%	41.7%	46.3%	8.2%	3.4%	0.3%	20.4%
442	44.3%	16.5%	29.1%	44.3%	47.9%	7.6%	2.8%	0.1%	13.5%

	Antihypertensive Medication Utilization by Medicare Beneficiaries								
	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin-Angiotensin System Antagonists	Combined Therapy
HRR	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion	Adjusted Proportion
443	32.9%	13.0%	28.5%	37.9%	45.6%	10.0%	2.0%	1.1%	27.4%
444	34.8%	12.9%	31.1%	40.6%	46.3%	8.2%	3.0%	0.5%	23.7%
445	31.8%	13.2%	28.0%	39.2%	48.8%	8.4%	2.5%	0.4%	22.3%
446	35.6%	11.6%	28.0%	44.4%	52.0%	7.2%	1.5%	0.3%	20.2%
447	35.0%	12.0%	27.9%	43.5%	51.1%	7.4%	1.9%	0.3%	23.0%
448	41.4%	12.9%	32.1%	48.2%	59.0%	7.8%	1.9%	0.2%	21.4%
449	39.3%	13.0%	31.6%	47.9%	50.7%	8.6%	2.2%	0.2%	18.6%
450	39.2%	13.4%	31.6%	47.8%	54.4%	7.7%	2.4%	0.2%	17.1%
451	33.5%	14.7%	30.2%	38.0%	44.2%	8.4%	2.4%	0.6%	25.6%
452	35.5%	13.3%	31.2%	45.8%	49.0%	9.0%	1.6%	0.3%	21.0%
456	37.4%	12.8%	30.8%	48.3%	53.8%	7.2%	2.8%	0.4%	19.8%
457	40.1%	13.8%	26.2%	44.4%	46.6%	8.6%	1.8%	0.4%	25.6%


Table 8. Dartmouth Atlas of Health Care Maps of the Proportion of Medicare Parts A, B, and D Beneficiaries With Hypertension and Use of One or More Antihypertensive Drugs, by Drug Class and Hospital Referral Region; Adjusted by Age Category, Gender, Race, and Comorbid Conditions, 2009




Proportion (%) of Hypertensive Beneficiaries
with Use of Angiotensin II Receptor Antagonists, 2009




Proportion (%) of Hypertensive Beneficiaries
with Use of Anti-adrenergic Agents, 2009




Proportion (%) of Hypertensive Beneficiaries
with Use of Beta Blockers, 2009




Proportion (%) of Hypertensive Beneficiaries
with Use of Calcium Channel Blockers, 2009




Proportion (%) of Hypertensive Beneficiaries
with Use of Combined Products, 2009



Proportion (%) of Hypertensive Beneficiaries
with Use of Diuretics, 2009



Proportion (%) of Hypertensive Beneficiaries
with Use of Other Renin-angiotensin System Antagonists, 2009



Proportion (%) of Hypertensive Beneficiaries
with Use of Vasodilators, 2009




Table 9. Proportion of Medicare Parts A, B, and D Beneficiaries With Hypertension and Use of Combination Drug, by Hospital Referral Region; Adjusted by Age Category, Gender, Race, and Comorbid Conditions, 2006-2009

Hospital Referral Region	Adjusted Proportion of Beneficiaries Using Combined Therapy			
	2006	2007	2008	2009
1	28.3%	29.3%	28.8%	27.6%
2	27.7%	28.4%	27.6%	26.4%
5	28.4%	29.5%	29.1%	27.7%
6	29.6%	30.2%	29.8%	28.6%
7	27.7%	27.8%	27.3%	26.2%
9	24.6%	26.0%	26.2%	25.8%
10	23.0%	23.9%	22.7%	22.3%
11	23.8%	24.7%	23.9%	22.9%
12	19.9%	21.8%	21.3%	20.3%
14	22.1%	21.2%	20.6%	18.9%
15	18.2%	20.2%	20.1%	19.5%
16	28.2%	28.3%	26.7%	25.2%
18	31.7%	32.3%	31.1%	29.7%
19	33.2%	33.2%	32.0%	30.3%
21	30.6%	30.1%	28.3%	26.1%
22	32.7%	31.7%	30.5%	28.0%
23	21.8%	23.5%	23.9%	23.5%
25	19.7%	21.4%	20.8%	20.4%
31	19.4%	20.8%	20.8%	20.2%
33	17.9%	19.4%	19.1%	18.0%
43	26.3%	27.0%	26.5%	25.7%
56	25.3%	25.8%	25.7%	24.9%
58	20.0%	21.4%	21.0%	19.6%
62	20.7%	21.5%	20.9%	19.8%
65	17.1%	17.4%	17.1%	16.2%
69	20.4%	22.7%	22.1%	21.5%
73	21.2%	22.8%	22.4%	22.0%
77	20.8%	22.0%	21.5%	20.5%
78	19.8%	23.2%	23.2%	23.6%
79	20.7%	21.8%	21.2%	20.2%
80	20.7%	22.1%	21.8%	21.1%
81	16.3%	17.3%	16.8%	16.2%
82	21.5%	23.2%	22.9%	22.2%
83	20.6%	20.6%	20.1%	19.4%
85	19.5%	20.8%	20.3%	20.0%

	Adjusted Proportion of Beneficiaries Using Combined Therapy			
Hospital Referral Region	2006	2007	2008	2009
86	21.3%	23.0%	22.3%	21.8%
87	18.9%	19.6%	18.2%	17.9%
89	19.7%	20.5%	20.7%	20.0%
91	20.2%	20.8%	20.2%	19.8%
96	22.1%	23.4%	23.1%	23.1%
101	22.1%	23.9%	23.6%	21.8%
102	22.3%	22.9%	22.0%	20.7%
103	23.2%	24.4%	24.1%	22.9%
104	25.0%	25.3%	24.7%	23.0%
105	24.6%	24.5%	24.2%	22.2%
106	23.9%	24.7%	23.4%	22.3%
107	20.6%	21.1%	20.1%	18.2%
109	21.0%	22.4%	21.8%	21.2%
110	18.7%	20.4%	19.9%	19.1%
111	18.1%	19.7%	19.4%	18.5%
112	23.6%	23.9%	23.8%	23.2%
113	23.4%	24.1%	23.7%	22.9%
115	27.9%	28.1%	26.3%	25.1%
116	22.4%	23.4%	22.2%	20.7%
118	23.0%	23.4%	23.3%	21.9%
119	25.4%	26.1%	25.3%	23.9%
120	23.2%	23.4%	22.8%	20.8%
122	23.7%	22.8%	21.9%	20.2%
123	23.5%	24.1%	23.4%	21.8%
124	25.8%	25.2%	23.9%	21.7%
127	27.4%	27.4%	26.8%	26.2%
129	24.7%	25.0%	24.1%	22.4%
130	25.9%	26.0%	24.7%	23.2%
131	22.2%	22.7%	22.2%	21.0%
133	29.0%	28.2%	26.9%	24.6%
134	27.7%	27.7%	26.8%	25.1%
137	27.4%	27.2%	26.4%	24.6%
139	22.2%	22.9%	21.4%	19.8%
140	29.7%	29.3%	28.0%	26.0%
141	27.6%	27.7%	26.5%	25.0%
142	26.9%	26.9%	27.0%	25.8%
144	27.7%	28.0%	27.1%	26.0%
145	31.9%	32.8%	31.9%	30.3%

	Adjusted Proportion of Beneficiaries Using Combined Therapy			
Hospital Referral Region	2006	2007	2008	2009
146	24.5%	26.8%	26.3%	25.0%
147	29.8%	29.8%	28.9%	27.9%
148	31.6%	32.7%	31.9%	29.7%
149	31.2%	31.2%	30.5%	29.3%
150	19.7%	21.2%	21.6%	21.2%
151	24.2%	25.3%	24.3%	22.7%
152	32.3%	31.6%	30.8%	28.6%
154	25.7%	25.5%	24.3%	22.4%
155	25.3%	26.1%	25.6%	23.7%
156	21.4%	21.9%	21.4%	20.6%
158	27.1%	28.3%	26.8%	24.4%
161	23.7%	24.2%	23.4%	22.3%
163	27.6%	28.1%	27.6%	25.9%
164	28.7%	29.7%	28.6%	26.1%
166	25.8%	26.4%	25.8%	24.3%
170	24.6%	25.0%	24.6%	23.2%
171	22.7%	22.8%	21.9%	20.6%
172	23.9%	24.3%	23.3%	21.7%
173	27.8%	27.6%	26.5%	25.1%
175	27.1%	26.5%	25.8%	23.8%
179	26.8%	27.2%	25.9%	24.6%
180	31.1%	31.5%	29.8%	27.5%
181	29.5%	30.3%	29.4%	27.7%
183	28.4%	29.2%	28.3%	26.8%
184	26.6%	26.9%	25.8%	23.9%
185	26.0%	28.0%	26.9%	26.1%
186	27.3%	27.2%	26.4%	25.1%
187	25.6%	26.4%	25.4%	23.6%
188	30.1%	30.2%	29.0%	27.4%
190	23.5%	24.1%	23.6%	22.5%
191	24.7%	25.0%	23.9%	23.1%
192	28.7%	29.0%	28.0%	26.3%
193	21.1%	21.9%	21.3%	20.0%
194	20.5%	20.4%	20.1%	18.5%
195	27.5%	27.3%	26.1%	24.5%
196	28.9%	28.7%	27.3%	25.4%
197	21.2%	22.1%	22.0%	21.6%
200	22.3%	23.6%	23.3%	22.1%

	Adjusted Proportion of Beneficiaries Using Combined Therapy			
Hospital Referral Region	2006	2007	2008	2009
201	28.6%	28.9%	28.0%	26.7%
203	25.1%	26.2%	25.2%	23.5%
204	24.0%	25.4%	24.8%	23.6%
205	27.4%	28.2%	27.7%	26.3%
207	22.9%	23.5%	22.8%	22.0%
208	25.3%	26.1%	24.9%	24.0%
209	29.3%	30.2%	29.2%	28.0%
210	29.5%	29.7%	28.7%	27.2%
212	29.5%	32.1%	30.8%	28.9%
213	35.7%	36.2%	34.7%	32.5%
214	29.0%	30.2%	29.8%	27.7%
216	26.2%	27.3%	26.9%	25.8%
217	35.1%	34.4%	32.7%	31.1%
218	26.0%	26.2%	26.2%	25.0%
219	25.7%	26.3%	25.7%	24.2%
220	32.8%	32.4%	31.0%	28.7%
221	13.3%	14.3%	14.0%	13.5%
222	13.6%	14.6%	14.0%	13.1%
223	24.3%	25.0%	24.3%	23.1%
225	23.6%	24.1%	23.4%	22.2%
226	27.2%	27.8%	27.8%	26.3%
227	12.8%	13.5%	13.2%	12.6%
230	14.9%	16.3%	15.5%	14.6%
231	10.2%	11.5%	11.4%	11.0%
232	23.9%	23.6%	22.7%	21.8%
233	24.6%	25.5%	24.3%	23.4%
234	23.0%	23.3%	23.2%	22.5%
235	21.4%	21.8%	21.3%	20.9%
236	26.0%	25.2%	24.4%	23.2%
238	26.6%	26.9%	26.0%	24.8%
239	24.1%	24.2%	23.5%	21.8%
240	23.9%	23.3%	21.8%	21.1%
242	25.3%	24.7%	24.0%	22.5%
243	24.3%	24.9%	23.6%	22.4%
244	24.4%	24.1%	23.7%	22.8%
245	25.8%	25.1%	25.1%	24.1%
246	24.1%	24.1%	23.3%	22.1%
248	31.1%	30.3%	29.0%	27.1%

	Adjusted Proportion of Beneficiaries Using Combined Therapy			
Hospital Referral Region	2006	2007	2008	2009
249	26.8%	25.7%	25.2%	23.5%
250	16.7%	16.6%	16.2%	15.0%
251	23.4%	23.4%	22.6%	21.4%
253	21.9%	22.0%	21.1%	19.7%
254	23.0%	23.1%	22.7%	21.2%
256	20.8%	21.7%	20.7%	19.8%
257	32.2%	32.5%	31.1%	28.8%
258	37.1%	37.4%	35.4%	34.0%
259	37.7%	36.5%	35.1%	33.5%
260	32.6%	31.8%	31.0%	29.8%
261	39.8%	37.7%	37.2%	34.9%
262	35.5%	34.5%	33.3%	31.0%
263	28.6%	29.5%	28.7%	26.7%
264	24.3%	25.2%	24.0%	22.1%
267	27.0%	27.2%	25.6%	24.0%
268	23.8%	24.8%	23.9%	22.2%
270	23.7%	23.8%	22.6%	20.9%
273	23.1%	23.7%	23.0%	21.9%
274	27.8%	28.7%	28.1%	26.3%
275	28.4%	28.6%	28.0%	25.8%
276	22.1%	22.3%	21.1%	20.2%
277	29.2%	29.3%	28.2%	26.3%
278	28.7%	28.9%	27.9%	26.0%
279	24.2%	24.3%	23.8%	22.2%
280	22.1%	22.7%	22.3%	20.7%
281	14.4%	14.7%	14.1%	13.2%
282	16.6%	17.2%	16.5%	15.1%
283	23.1%	23.2%	23.0%	22.1%
284	26.5%	26.2%	26.2%	25.8%
285	26.8%	27.3%	27.3%	26.2%
288	23.9%	24.0%	24.1%	23.2%
289	29.4%	29.3%	29.3%	28.8%
291	25.9%	25.9%	25.4%	25.1%
292	22.0%	23.3%	24.0%	23.5%
293	19.2%	20.1%	19.8%	18.8%
295	16.3%	17.7%	18.4%	17.7%
296	21.0%	21.6%	22.1%	21.8%
297	18.4%	18.8%	19.4%	19.3%


	Adjusted Proportion of Beneficiaries Using Combined Therapy			
Hospital Referral Region	2006	2007	2008	2009
299	18.1%	19.4%	20.4%	19.5%
300	17.9%	19.1%	20.2%	19.1%
301	20.6%	21.0%	21.6%	21.5%
303	24.4%	23.8%	23.9%	24.2%
304	16.1%	16.8%	17.3%	16.2%
307	16.6%	18.4%	19.6%	19.1%
308	18.9%	19.8%	20.1%	19.8%
309	25.3%	26.3%	25.4%	23.4%
311	30.0%	31.0%	30.0%	27.8%
312	26.2%	26.5%	26.1%	25.0%
313	26.7%	26.9%	26.5%	25.2%
314	29.7%	30.0%	29.2%	28.0%
315	30.0%	30.5%	30.0%	28.2%
318	30.9%	30.5%	30.1%	28.9%
319	32.2%	32.3%	31.3%	29.8%
320	24.6%	25.3%	24.7%	23.5%
321	27.4%	27.2%	26.2%	25.8%
322	27.9%	28.0%	27.2%	25.9%
323	22.6%	23.3%	22.3%	20.8%
324	24.4%	25.0%	24.0%	23.2%
325	19.9%	21.9%	21.4%	20.3%
326	21.6%	23.7%	22.6%	21.4%
327	23.4%	25.3%	24.5%	23.3%
328	20.8%	22.3%	21.8%	21.0%
329	25.4%	26.6%	25.6%	24.3%
330	25.2%	26.4%	25.1%	23.6%
331	26.8%	27.7%	27.2%	26.2%
332	26.3%	26.5%	25.7%	24.3%
334	23.9%	24.7%	24.3%	22.4%
335	21.9%	22.7%	22.3%	20.6%
336	31.2%	31.8%	31.1%	29.3%
339	29.3%	29.3%	28.3%	26.8%
340	27.8%	28.1%	26.9%	25.0%
341	23.4%	22.9%	22.2%	20.3%
342	21.9%	21.3%	20.2%	19.1%
343	20.7%	20.6%	20.0%	19.3%
344	20.6%	21.1%	20.4%	19.2%
345	21.0%	21.2%	18.9%	17.5%

	Adjusted Proportion of Beneficiaries Using Combined Therapy			
Hospital Referral Region	2006	2007	2008	2009
346	22.0%	24.1%	23.6%	22.9%
347	20.5%	22.0%	21.4%	19.6%
350	21.4%	22.7%	21.9%	20.9%
351	19.6%	21.5%	21.0%	19.9%
352	20.5%	21.7%	20.9%	19.9%
354	23.5%	24.7%	24.6%	23.7%
355	20.9%	22.2%	21.9%	21.0%
356	20.3%	21.2%	20.7%	20.3%
357	22.0%	23.6%	23.0%	21.4%
358	22.6%	23.9%	24.3%	23.5%
359	21.8%	23.9%	23.1%	21.5%
360	22.1%	25.1%	24.8%	23.7%
362	19.9%	22.8%	22.7%	22.3%
363	19.8%	21.1%	20.3%	19.7%
364	16.0%	17.8%	17.4%	16.6%
365	33.3%	32.2%	30.9%	28.7%
366	34.0%	33.6%	32.5%	30.4%
367	36.5%	35.9%	35.0%	32.6%
368	30.9%	30.5%	29.4%	27.4%
369	32.8%	33.0%	31.7%	29.6%
370	27.0%	27.6%	26.1%	23.9%
371	27.4%	27.4%	26.2%	24.5%
373	30.1%	30.8%	29.7%	27.6%
374	29.7%	30.7%	29.6%	27.6%
375	23.9%	25.6%	24.7%	24.6%
376	26.4%	26.7%	26.3%	25.4%
377	25.8%	27.1%	26.5%	25.2%
379	32.7%	32.7%	31.9%	30.4%
380	26.4%	27.3%	26.7%	25.3%
382	29.9%	30.0%	28.8%	26.9%
383	30.2%	30.7%	30.2%	28.6%
385	23.9%	25.8%	24.7%	23.3%
386	30.2%	31.0%	30.2%	28.9%
388	28.1%	29.1%	27.3%	24.7%
390	29.7%	29.4%	28.6%	27.3%
391	28.3%	29.0%	28.0%	26.3%
393	28.5%	27.2%	26.6%	25.2%
394	25.9%	27.4%	26.5%	25.3%


	Adjusted Proportion of Beneficiaries Using Combined Therapy			
Hospital Referral Region	2006	2007	2008	2009
396	27.6%	26.8%	26.9%	26.7%
397	27.6%	28.5%	27.8%	26.6%
399	29.6%	30.2%	28.6%	27.0%
400	29.0%	29.6%	28.2%	26.4%
402	31.5%	30.4%	30.7%	30.3%
406	32.7%	33.4%	32.5%	30.8%
411	30.5%	29.2%	28.0%	25.9%
412	27.1%	25.9%	25.4%	24.1%
413	22.0%	22.4%	21.6%	19.7%
416	29.6%	29.4%	28.8%	26.1%
417	31.5%	31.1%	29.8%	27.8%
418	26.5%	28.4%	27.2%	25.6%
420	28.8%	29.8%	29.0%	27.5%
421	27.6%	26.8%	27.0%	25.4%
422	33.8%	35.2%	34.7%	33.1%
423	29.2%	30.1%	29.1%	27.5%
424	16.4%	17.1%	17.1%	16.4%
426	26.7%	26.8%	26.8%	25.7%
427	21.2%	22.0%	21.3%	20.2%
428	22.0%	22.8%	22.9%	21.2%
429	25.0%	27.2%	26.3%	25.2%
430	22.9%	24.1%	23.7%	22.9%
431	23.1%	23.9%	23.8%	22.6%
432	25.5%	25.8%	25.1%	23.5%
435	27.0%	27.1%	26.0%	24.6%
437	15.7%	16.2%	15.9%	15.1%
438	18.5%	19.6%	19.1%	17.9%
439	17.5%	18.9%	18.4%	17.3%
440	18.9%	19.8%	19.2%	18.1%
441	20.7%	22.3%	21.3%	20.4%
442	13.9%	15.1%	14.8%	13.5%
443	28.0%	29.0%	28.8%	27.4%
444	25.1%	25.8%	25.1%	23.7%
445	24.0%	23.8%	23.4%	22.3%
446	20.7%	22.3%	21.5%	20.2%
447	24.6%	25.1%	24.1%	23.0%
448	21.7%	23.5%	22.4%	21.4%
449	19.0%	19.9%	19.6%	18.6%

	Adjusted Proportion of Beneficiaries Using Combined Therapy			
Hospital Referral Region	2006	2007	2008	2009
450	18.9%	19.6%	18.6%	17.1%
451	26.7%	27.6%	26.8%	25.6%
452	24.6%	24.5%	23.3%	21.0%
456	20.9%	21.8%	21.2%	19.8%
457	27.3%	28.2%	26.9%	25.6%


Table 10. Dartmouth Atlas of Health Care Maps of the Proportion of Medicare Parts A, B, and D Beneficiaries With Hypertension and Use of Combination Drug, by Hospital Referral Region; Adjusted by Age Category, Gender, Race, and Comorbid Conditions, 2006-2009



Combined Product, 2007



Combined Product, 2008



Combined Product, 2009




Table 11. Annual Mean Number of Antihypertensive Drug Classes Used by Medicare Parts A, B, and D Beneficiaries With Hypertension, by Hospital Referral Region, 2006-2009

Hospital Referral Region	Number of Antihypertensive Medication Classes Used by Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
	2006	2007	2008	2009
1	2.0	2.0	2.0	2.0
2	2.1	2.0	2.0	2.0
5	2.0	1.9	1.9	1.9
6	2.0	1.9	1.9	1.9
7	2.0	2.0	2.0	2.0
9	2.0	1.9	1.9	2.0
10	1.9	1.9	1.9	1.9
11	1.9	1.9	1.9	1.8
12	1.9	1.8	1.8	1.8
14	1.9	1.8	1.8	1.8
15	1.9	1.9	1.9	1.8
16	1.9	1.9	1.9	1.8
18	2.0	1.9	2.0	1.9
19	2.0	1.9	1.9	1.9
21	1.9	1.9	1.9	1.8
22	2.0	1.9	1.9	1.9
23	1.9	1.8	1.8	1.8
25	1.9	1.9	1.9	1.9
31	1.9	1.8	1.8	1.8
33	1.9	1.9	1.9	1.9
43	1.9	1.9	1.9	1.9
56	1.9	1.9	1.9	1.9
58	2.0	2.0	2.0	1.9
62	1.8	1.8	1.8	1.8
65	1.9	1.9	1.9	1.9
69	1.8	1.7	1.7	1.7
73	1.8	1.8	1.8	1.8
77	1.9	1.9	1.9	1.9
78	1.9	1.8	1.8	1.8

	Number of Antihypertensive Medication Classes Used by Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
79	1.9	1.9	1.9	1.9
80	1.9	1.9	1.9	1.9
81	1.9	1.9	1.9	1.9
82	2.0	2.0	1.9	2.0
83	1.9	1.8	1.8	1.8
85	1.9	1.8	1.8	1.8
86	1.8	1.7	1.7	1.7
87	1.8	1.8	1.8	1.8
89	1.8	1.8	1.8	1.8
91	2.0	2.0	2.0	2.0
96	1.8	1.8	1.8	1.8
101	1.8	1.8	1.7	1.7
102	1.9	1.9	1.8	1.8
103	1.9	1.9	1.9	1.8
104	2.0	1.9	1.9	1.8
105	1.9	1.8	1.9	1.8
106	2.0	1.9	1.9	1.9
107	1.9	1.8	1.8	1.7
109	1.8	1.8	1.8	1.8
110	1.9	1.9	1.9	1.9
111	1.9	1.9	1.9	1.9
112	1.9	1.8	1.8	1.8
113	2.0	1.9	1.9	2.0
115	1.8	1.7	1.7	1.7
116	1.8	1.8	1.8	1.8
118	1.8	1.8	1.8	1.8
119	1.9	1.8	1.8	1.8
120	2.0	1.9	2.0	1.9
122	1.9	1.9	1.8	1.8
123	2.1	2.0	2.0	2.0
124	1.9	1.9	1.9	1.9

	Number of Antihypertensive Medication Classes Used by Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
127	1.9	1.9	1.9	1.9
129	1.9	1.9	1.9	1.8
130	1.9	1.9	1.9	1.9
131	1.9	1.8	1.8	1.8
133	2.1	2.0	2.0	2.0
134	2.1	2.0	2.0	1.9
137	1.8	1.8	1.8	1.8
139	1.8	1.8	1.8	1.8
140	2.0	1.9	1.9	1.9
141	1.9	1.9	1.9	1.9
142	2.0	2.0	2.0	2.0
144	2.0	2.0	2.0	2.0
145	2.0	2.0	2.0	2.0
146	2.0	2.0	2.0	2.0
147	2.0	2.0	2.0	2.0
148	1.9	1.9	1.9	1.9
149	2.0	1.9	1.9	1.9
150	1.7	1.6	1.6	1.6
151	2.0	1.9	1.9	1.9
152	1.9	1.8	1.8	1.8
154	2.0	2.0	2.0	1.9
155	1.9	1.9	2.0	1.9
156	2.0	2.0	2.0	2.0
158	2.0	1.9	1.9	1.9
161	1.9	1.9	1.9	1.9
163	2.0	1.9	1.9	1.9
164	1.9	1.9	1.9	1.9
166	2.0	1.9	1.9	1.9
170	2.0	2.0	2.0	1.9
171	2.1	2.0	2.1	2.0
172	2.1	2.0	2.0	2.0

	Number of Antihypertensive Medication Classes Used by Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
173	2.0	2.0	2.0	1.9
175	2.0	2.0	2.0	1.9
179	2.1	2.0	2.0	1.9
180	2.0	2.0	2.0	1.9
181	2.0	2.0	2.0	1.9
183	2.1	2.0	2.0	2.0
184	2.1	2.0	2.0	2.0
185	2.1	2.0	2.0	2.0
186	2.0	1.9	1.9	1.9
187	2.0	1.9	1.9	1.9
188	2.1	2.1	2.1	2.0
190	2.1	2.0	2.0	2.0
191	2.0	1.9	1.9	1.9
192	2.0	2.0	2.0	1.9
193	2.0	1.9	1.9	1.9
194	2.0	2.0	2.0	1.9
195	2.1	2.0	2.0	2.0
196	2.0	2.0	2.0	2.0
197	2.1	2.1	2.1	2.0
200	1.9	1.9	1.9	1.9
201	2.0	1.9	1.9	1.9
203	2.1	2.0	2.0	2.0
204	2.1	2.1	2.1	2.0
205	2.0	2.0	2.0	2.0
207	2.0	1.9	1.9	1.9
208	2.1	2.0	2.0	2.0
209	2.0	2.0	2.0	2.0
210	2.1	2.1	2.1	2.1
212	2.1	2.1	2.1	2.0
213	2.0	2.0	2.0	2.0
214	2.0	2.0	2.0	2.0

	Number of Antihypertensive Medication Classes Used by Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
216	2.0	2.0	2.1	2.0
217	2.1	2.1	2.1	2.1
218	2.0	2.1	2.1	2.1
219	2.0	2.0	2.0	2.0
220	1.9	1.9	2.0	1.9
221	1.9	1.9	1.9	1.9
222	1.9	1.9	1.9	1.9
223	1.9	1.9	1.9	1.9
225	2.0	2.0	1.9	1.9
226	1.9	1.9	1.9	1.9
227	1.9	1.9	1.9	1.9
230	2.0	1.9	1.9	1.9
231	1.8	1.9	1.9	1.8
232	2.0	1.9	1.9	1.9
233	1.9	1.9	1.9	1.9
234	2.1	2.0	2.1	2.1
235	1.9	1.9	1.9	1.9
236	2.0	2.0	2.0	1.9
238	2.0	2.0	2.0	1.9
239	2.0	1.9	1.9	1.9
240	2.0	1.9	1.9	1.9
242	2.0	1.9	1.9	1.9
243	1.9	1.9	1.8	1.8
244	1.8	1.8	1.8	1.8
245	1.9	1.9	1.9	1.9
246	2.0	1.9	1.9	1.9
248	2.1	2.0	2.0	1.9
249	1.9	1.9	1.9	1.8
250	2.1	2.0	2.1	2.0
251	2.0	2.0	2.0	2.0
253	2.1	2.1	2.1	2.1

	Number of Antihypertensive Medication Classes Used by Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
254	2.0	2.0	2.0	2.0
256	2.0	2.0	2.0	2.0
257	1.9	1.9	1.9	1.9
258	1.9	1.9	2.0	2.0
259	1.9	1.9	1.9	2.0
260	1.9	1.9	1.9	2.0
261	1.9	1.9	2.0	2.0
262	1.9	1.9	2.0	1.9
263	2.1	2.0	2.0	2.0
264	2.0	1.9	1.9	1.9
267	2.0	2.0	2.0	1.9
268	2.1	2.0	2.0	1.9
270	2.0	2.0	2.0	1.9
273	2.1	2.0	2.0	2.0
274	1.9	1.9	1.9	1.9
275	1.9	1.9	1.9	1.9
276	1.9	1.9	1.9	1.9
277	2.0	1.9	2.0	1.9
278	2.1	2.0	2.0	2.0
279	1.9	1.8	1.8	1.8
280	1.8	1.8	1.8	1.8
281	2.0	2.0	2.0	1.9
282	1.9	1.9	1.9	1.8
283	1.9	1.9	1.9	1.9
284	1.9	1.8	1.8	1.8
285	1.9	1.8	1.8	1.8
288	1.9	1.9	1.9	1.9
289	1.9	1.9	1.9	1.9
291	1.9	1.8	1.8	1.8
292	1.8	1.8	1.8	1.8
293	1.8	1.8	1.8	1.8


	Number of Antihypertensive Medication Classes Used by Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
295	1.9	1.9	1.9	1.9
296	1.9	1.9	1.9	1.9
297	2.0	2.0	2.0	2.0
299	1.9	1.9	1.9	1.9
300	1.9	1.9	1.9	1.9
301	1.8	1.8	1.8	1.8
303	2.0	2.0	2.0	2.0
304	1.9	1.9	2.0	1.9
307	1.8	1.8	1.9	1.9
308	1.8	1.8	1.8	1.8
309	2.0	1.9	1.9	1.9
311	2.0	2.0	2.0	1.9
312	2.1	2.0	2.0	2.0
313	2.1	2.0	2.0	2.0
314	2.1	2.0	2.0	2.0
315	2.0	1.9	1.9	1.9
318	2.1	2.0	2.0	2.0
319	2.0	1.9	1.9	1.9
320	2.1	2.0	2.0	1.9
321	2.1	2.0	2.0	2.0
322	2.0	2.0	2.0	2.0
323	2.1	2.0	2.0	2.0
324	2.0	2.0	2.0	2.1
325	1.9	1.9	1.9	1.9
326	2.1	2.0	2.0	2.0
327	2.0	1.9	2.0	1.9
328	2.1	2.0	2.0	2.0
329	2.1	2.0	2.0	2.0
330	2.0	2.0	2.0	1.9
331	2.0	2.0	2.0	1.9
332	2.0	2.0	2.0	1.9

	Number of Antihypertensive Medication Classes Used by Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
334	2.0	2.0	2.0	1.9
335	1.9	1.8	1.8	1.8
336	1.9	2.0	2.0	2.0
339	1.9	1.9	1.9	1.9
340	2.0	2.0	2.0	1.9
341	2.0	1.9	1.9	1.8
342	1.9	1.9	1.9	1.9
343	1.9	1.9	1.9	1.8
344	2.0	2.0	2.0	2.0
345	2.0	2.0	2.0	2.0
346	1.8	1.9	1.9	1.9
347	1.9	1.9	1.9	1.9
350	1.9	1.9	1.9	1.9
351	1.9	1.9	1.9	1.9
352	1.9	2.0	2.0	1.9
354	1.8	1.8	1.8	1.9
355	1.9	1.9	1.9	1.9
356	1.9	1.9	1.9	1.9
357	1.8	1.8	1.8	1.8
358	1.8	1.9	1.9	1.9
359	1.9	1.9	1.9	1.9
360	1.8	1.8	1.8	1.8
362	1.8	1.8	1.8	1.8
363	1.9	1.9	1.9	1.9
364	1.9	1.9	1.9	1.9
365	2.0	1.9	1.9	1.9
366	2.0	1.9	2.0	1.9
367	2.1	2.1	2.1	2.1
368	2.0	1.9	1.9	1.8
369	2.0	1.9	1.9	1.9
370	2.0	1.9	1.9	1.9


	Number of Antihypertensive Medication Classes Used by Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
371	2.0	1.9	2.0	2.0
373	1.9	1.9	1.9	1.9
374	2.0	2.0	2.0	2.0
375	2.0	2.0	2.0	2.0
376	2.0	2.0	2.0	2.0
377	2.1	2.0	2.0	2.0
379	2.1	2.0	2.0	2.0
380	2.0	2.0	2.0	2.0
382	1.9	1.9	1.9	1.8
383	2.0	2.0	2.0	1.9
385	1.9	1.9	1.9	1.9
386	2.0	2.0	2.0	1.9
388	2.0	2.0	2.0	1.9
390	1.8	1.8	1.8	1.8
391	2.0	1.9	1.9	1.9
393	1.8	1.8	1.8	1.8
394	2.0	2.0	2.0	1.9
396	1.8	1.8	1.8	1.8
397	2.0	2.0	2.0	1.9
399	1.9	1.9	1.9	1.9
400	2.0	1.9	1.9	1.9
402	1.8	1.7	1.8	1.8
406	1.9	1.9	1.9	1.8
411	2.0	1.9	1.9	1.9
412	1.8	1.8	1.8	1.8
413	2.0	2.0	2.0	1.9
416	2.0	1.9	1.9	1.9
417	2.0	2.0	2.0	1.9
418	2.0	2.0	1.9	1.9
420	2.0	2.0	2.0	1.9
421	1.9	1.9	1.9	1.8

	Number of Antihypertensive Medication Classes Used by Beneficiaries With Hypertension and Any Antihypertensive Medication Use			
Hospital Referral Region	2006	2007	2008	2009
422	1.8	1.8	1.8	1.8
423	1.9	1.9	1.9	1.8
424	1.9	1.9	1.9	1.9
426	1.9	1.9	1.9	1.9
427	2.0	2.0	2.0	1.9
428	2.0	2.0	2.0	1.9
429	2.0	2.0	2.0	1.9
430	2.0	2.0	2.0	1.9
431	2.0	2.0	2.0	2.0
432	2.0	1.9	1.9	1.9
435	2.0	2.0	2.0	1.9
437	2.0	2.0	2.0	2.0
438	2.0	1.9	1.9	1.9
439	2.0	2.0	2.0	2.0
440	2.0	1.9	1.9	1.9
441	2.0	2.0	2.0	2.0
442	2.1	2.0	2.0	2.0
443	2.0	1.9	2.0	1.9
444	2.0	2.0	2.0	2.0
445	2.0	1.9	1.9	1.9
446	2.0	2.0	2.0	1.9
447	2.0	2.0	2.0	1.9
448	2.2	2.1	2.2	2.1
449	2.0	2.0	2.0	2.0
450	2.1	2.1	2.1	2.1
451	2.0	1.9	2.0	1.9
452	2.0	2.0	2.0	2.0
456	2.1	2.1	2.1	2.1
457	2.0	1.9	1.9	1.9


Table 12. Dartmouth Atlas of Health Care Maps of the Number of Antihypertensive Drug Classes Used by Medicare Parts A, B, and D Beneficiaries With Hypertension, by Hospital Referral Region, 2006-2009



Annual Mean Number of Classes, 2007



Annual Mean Number of Classes, 2008



Annual Mean Number of Classes, 2009




Table 13. Number of Prescription Claims for Antihypertensive Drugs Among Medicare Parts A, B, and D Beneficiaries With Hypertension, 2006-2009

Note: Age is calculated as of December 31 of the year. Note: An asterisk (*) signifies small cell count (<11).

Breakdown	Category	Year	Number of Prescriptions (in 100,000s)								
			ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vaso-dilators	Other Renin Angiotensin Antagonists	Combined Therapy
Total	All	2006	151.84	64.02	144.11	182.77	198.46	39.00	6.86	0.35	111.68
Age*	Under 65	2006	30.03	9.51	22.07	31.24	34.16	8.02	1.81	0.06	17.73
	65 to 74	2006	50.34	21.39	45.35	52.14	64.04	12.65	1.88	0.12	43.12
	75 to 84	2006	46.39	22.08	48.90	58.04	65.19	12.47	2.04	0.12	36.65
	85 and older	2006	25.08	11.03	27.79	41.36	35.07	5.86	1.13	0.05	14.18
Gender	Male	2006	55.79	18.00	42.00	53.07	66.84	19.06	2.69	0.21	31.01
	Female	2006	96.04	46.02	102.11	129.70	131.61	19.93	4.17	0.14	80.67
Race	White	2006	118.74	47.87	103.56	143.25	156.81	27.07	3.88	0.29	83.18
	Black	2006	22.25	8.92	27.90	29.76	26.86	9.00	2.52	0.03	19.68
	Other	2006	1.72	1.08	1.99	1.56	2.47	0.47	0.08	0.00	1.41
	Asian	2006	2.78	3.27	5.23	2.52	5.15	1.05	0.14	0.01	3.36
	Hispanic	2006	5.40	2.62	4.85	4.83	6.32	1.21	0.21	0.01	3.77
	American Indian/Alaska Native	2006	0.95	0.25	0.58	0.86	0.84	0.19	0.03	*	0.28
Comorbid Condition	Diabetes	2006	77.93	31.97	62.81	92.41	89.44	19.45	4.13	0.19	45.98
	Cancer	2006	26.91	12.33	27.59	33.99	38.48	7.61	1.21	0.09	20.03
	Osteoporosis	2006	20.06	10.62	22.66	26.85	29.13	4.11	0.73	0.04	16.48
	Osteoarthritis	2006	57.48	27.40	59.87	80.18	79.01	15.27	2.67	0.14	46.10
	Hyperlipidemic	2006	103.11	45.82	94.76	114.78	138.63	24.95	4.38	0.28	79.60
	Cardiovascular disease	2006	88.50	37.09	80.93	122.04	130.46	23.06	5.32	0.32	46.91
Total	All	2007	240.51	100.24	221.75	274.07	328.84	58.25	10.93	1.11	188.70
Age**	Under 65	2007	41.99	12.42	29.18	41.90	48.63	10.75	2.60	0.15	25.43
	65 to 74	2007	82.89	33.53	70.31	79.90	107.70	19.23	3.03	0.39	74.68
	75 to 84	2007	75.10	35.50	76.87	88.77	111.13	19.06	3.33	0.41	63.03
	85 and older	2007	40.54	18.79	45.38	63.50	61.38	9.21	1.97	0.16	25.56
Gender	Male	2007	92.05	28.79	66.57	83.65	113.46	29.71	4.37	0.52	54.37
	Female	2007	148.47	71.45	155.17	190.42	215.37	28.54	6.56	0.59	134.33
Race	White	2007	196.14	79.25	168.83	222.90	271.24	42.69	6.56	0.89	148.77
	Black	2007	29.75	11.47	36.67	38.39	37.44	11.74	3.70	0.13	27.89

			Number of Prescriptions (in 100,000s)								
Breakdown	Category	Year	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vaso-dilators	Other Renin Angiotensin Antagonists	Combined Therapy
	Other	2007	2.64	1.68	2.97	2.30	3.82	0.70	0.12	0.02	2.33
	Asian	2007	3.61	4.19	6.47	3.20	6.78	1.32	0.19	0.04	4.45
	Hispanic	2007	6.86	3.26	5.92	5.92	8.18	1.52	0.30	0.03	4.84
	American Indian/Alaska Native	2007	1.51	0.40	0.89	1.36	1.38	0.28	0.04	0.00	0.43
Comorbid Condition	Diabetes	2007	117.31	47.46	92.58	133.15	141.79	28.28	6.46	0.59	74.01
	Cancer	2007	45.95	20.94	45.85	54.81	68.39	12.19	2.06	0.26	36.26
	Osteoporosis	2007	31.77	16.90	35.18	40.28	48.43	6.08	1.17	0.17	27.38
	Osteoarthritis	2007	87.81	41.28	88.74	116.59	126.99	22.23	4.21	0.47	73.65
	Hyperlipidemic	2007	170.59	73.79	152.06	181.76	238.31	39.15	7.38	0.91	137.71
	Cardiovascular disease	2007	134.42	56.10	119.94	176.95	210.37	33.24	8.30	0.85	75.16
Total	All	2008	239.12	100.86	225.87	276.44	343.43	58.08	12.30	2.63	185.26
Age*	Under 65	2008	42.99	12.50	30.37	43.22	51.62	11.13	2.98	0.34	25.38
	65 to 74	2008	82.01	33.56	72.06	80.87	112.19	19.13	3.41	0.92	73.45
	75 to 84	2008	73.02	35.17	76.69	87.64	113.74	18.58	3.67	0.96	60.85
	85 and older	2008	41.10	19.63	46.75	64.72	65.88	9.24	2.25	0.41	25.58
Gender	Male	2008	93.19	29.50	69.77	86.30	120.97	29.96	4.94	0.97	54.74
	Female	2008	145.93	71.36	156.10	190.14	222.46	28.12	7.37	1.66	130.53
Race	White	2008	194.15	79.33	171.48	224.37	282.69	42.35	7.30	2.02	145.36
	Black	2008	29.88	11.53	37.49	38.79	39.24	11.83	4.21	0.33	27.59
	Other	2008	2.78	1.81	3.15	2.47	4.22	0.74	0.15	0.05	2.45
	Asian	2008	3.75	4.48	6.76	3.36	7.33	1.34	0.23	0.13	4.72
	Hispanic	2008	6.96	3.26	6.02	5.97	8.42	1.52	0.36	0.09	4.71
	American Indian/Alaska Native	2008	1.60	0.45	0.96	1.49	1.52	0.30	0.05	0.01	0.44
Comorbid Condition	Diabetes	2008	117.63	48.51	96.61	136.28	151.44	28.91	7.45	1.43	74.00
	Cancer	2008	46.81	21.58	47.68	56.62	73.20	12.36	2.38	0.59	36.47
	Osteoporosis	2008	32.92	17.70	36.97	42.04	52.51	6.25	1.39	0.46	27.87
	Osteoarthritis	2008	88.94	41.92	91.25	119.47	134.45	22.44	4.90	1.17	73.17
	Hyperlipidemic	2008	173.14	75.69	158.99	188.87	254.05	40.20	8.62	2.15	137.68
	Cardiovascular disease	2008	133.09	56.58	122.19	178.48	220.26	33.27	9.39	1.76	73.58

			Number of Prescriptions (in 100,000s)								
Breakdown	Category	Year	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vaso-dilators	Other Renin Angiotensin Antagonists	Combined Therapy
Total	All	2009	235.94	97.53	228.77	268.55	338.72	56.54	13.94	3.69	174.26
Age*	Under 65	2009	44.29	12.16	31.82	43.49	52.74	11.41	3.37	0.48	24.88
	65 to 74	2009	80.03	32.17	73.07	77.24	109.20	18.23	3.87	1.28	68.67
	75 to 84	2009	70.52	33.57	76.06	83.44	109.89	17.73	4.11	1.32	56.30
	85 and older	2009	41.11	19.64	47.82	64.39	66.89	9.16	2.59	0.61	24.40
Gender	Male	2009	93.17	28.80	72.54	85.21	121.03	29.34	5.57	1.31	52.38
	Female	2009	142.78	68.73	156.23	183.34	217.69	27.20	8.38	2.39	121.87
Race	White	2009	189.56	75.70	171.96	215.82	276.18	40.63	8.14	2.77	134.85
	Black	2009	30.69	11.49	39.16	39.03	40.16	11.93	4.85	0.50	27.05
	Other	2009	2.91	1.89	3.34	2.56	4.44	0.77	0.18	0.08	2.49
	Asian	2009	3.83	4.63	6.91	3.40	7.55	1.32	0.27	0.20	4.66
	Hispanic	2009	7.34	3.39	6.36	6.21	8.80	1.59	0.44	0.14	4.77
	American Indian/Alaska Native	2009	1.62	0.44	1.04	1.53	1.58	0.31	0.06	0.01	0.43
Comorbid Condition	Diabetes	2009	117.10	47.69	100.12	134.92	152.44	28.86	8.62	2.05	71.19
	Cancer	2009	46.68	21.20	48.87	55.83	73.04	12.19	2.74	0.83	34.83
	Osteoporosis	2009	33.14	17.58	37.90	41.59	52.76	6.23	1.62	0.67	26.68
	Osteoarthritis	2009	89.30	41.31	93.34	118.30	134.75	22.28	5.69	1.67	69.96
	Hyperlipidemic	2009	173.86	74.52	164.82	187.70	254.72	40.09	10.07	3.03	131.61
	Cardiovascular disease	2009	130.61	54.74	123.37	175.07	217.36	32.77	10.67	2.40	68.90

Table 13b. Number of Prescriptions per Medication Class by Year among beneficiaries enrolled in Medicare Parts A, B, and D - By Antihypertensive Medication Class

Breakdown	Category	Year	Number of Prescriptions (in 100,000s)								
			ACE Inhibitor	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vaso-dilators	Other Renin Angiotensin Antagonists	Combined Therapy
Total	All	2006	165.95	67.82	154.29	208.35	220.77	43.18	7.16	0.40	119.13
Age*	Under 65	2006	33.58	10.22	24.04	37.61	40.17	9.48	1.92	0.07	19.31
	65 to 74	2006	54.72	22.61	48.35	57.79	70.57	13.83	1.94	0.14	45.86
	75 to 84	2006	50.12	23.25	51.97	64.62	71.14	13.49	2.11	0.14	38.72
	85 and older	2006	27.54	11.74	29.94	48.33	38.89	6.38	1.19	0.06	15.24
Gender	Male	2006	62.24	19.34	45.47	61.51	76.46	22.10	2.84	0.25	33.26
	Female	2006	103.71	48.47	108.82	146.83	144.30	21.08	4.32	0.15	85.87
Race	White	2006	130.84	51.05	112.01	165.99	176.66	30.53	4.07	0.34	89.49
	Black	2006	23.42	9.23	29.01	31.66	28.24	9.42	2.61	0.04	20.47
	Other	2006	1.87	1.13	2.11	1.73	2.70	0.52	0.08	0.01	1.48
	Asian	2006	2.99	3.40	5.45	2.74	5.49	1.15	0.14	0.01	3.48
	Hispanic	2006	5.76	2.73	5.07	5.23	6.72	1.33	0.22	0.01	3.91
	American Indian/Alaska Native	2006	1.07	0.27	0.63	1.00	0.95	0.22	0.03	0.00	0.31
Comorbid Condition	Diabetes	2006	83.75	33.45	65.61	101.01	95.34	20.45	4.25	0.21	47.94
	Cancer	2006	28.97	12.94	29.30	38.13	42.15	8.30	1.25	0.10	21.18
	Osteoporosis	2006	21.06	10.95	23.60	29.87	31.15	4.31	0.74	0.04	17.09
	Osteoarthritis	2006	60.51	28.36	62.34	88.04	84.12	16.15	2.72	0.15	47.93
	Hyperlipidemic	2006	108.94	47.42	98.20	122.94	148.25	26.37	4.47	0.31	82.18
	Cardiovascular disease	2006	95.59	38.88	85.13	136.52	142.00	24.26	5.49	0.37	48.79
Total	All	2007	262.14	106.28	237.27	309.44	364.90	64.47	11.37	1.21	201.53
Age*	Under 65	2007	46.72	13.38	31.73	49.83	56.68	12.63	2.74	0.17	27.62
	65 to 74	2007	90.23	35.59	75.16	88.47	119.24	21.20	3.13	0.43	79.86
	75 to 84	2007	81.00	37.37	81.67	98.19	121.33	20.67	3.44	0.43	66.70
	85 and older	2007	44.19	19.94	48.71	72.95	67.65	9.97	2.06	0.18	27.35
Gender	Male	2007	102.33	31.00	71.97	95.80	129.15	34.35	4.61	0.59	58.36
	Female	2007	159.81	75.28	165.29	213.64	235.76	30.11	6.76	0.62	143.17
Race	White	2007	215.08	84.45	182.08	254.77	303.95	47.95	6.86	0.98	159.93
	Black	2007	31.29	11.87	38.13	40.71	39.30	12.29	3.82	0.13	29.03
	Other	2007	2.87	1.77	3.14	2.54	4.17	0.78	0.13	0.02	2.45

Breakdown	Category	Year	Number of Prescriptions (in 100,000s)								
			ACE Inhibitor	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vaso-dilators	Other Renin Angiotensin Antagonists	Combined Therapy
	Asian	2007	3.88	4.36	6.76	3.48	7.22	1.45	0.20	0.04	4.61
	Hispanic	2007	7.33	3.39	6.19	6.39	8.70	1.67	0.32	0.03	5.04
	American Indian/Alaska Native	2007	1.69	0.43	0.96	1.56	1.55	0.32	0.05	0.00	0.47
Comorbid Condition	Diabetes	2007	125.55	49.62	96.50	144.38	150.73	29.68	6.63	0.62	77.05
	Cancer	2007	49.33	21.96	48.63	61.08	74.89	13.33	2.12	0.28	38.33
	Osteoporosis	2007	33.23	17.39	36.61	44.31	51.70	6.36	1.19	0.17	28.35
	Osteoarthritis	2007	92.14	42.66	92.27	126.99	135.00	23.52	4.29	0.49	76.55
	Hyperlipidemic	2007	179.69	76.26	157.39	193.86	254.28	41.37	7.53	0.97	142.01
	Cardiovascular disease	2007	144.63	58.75	125.80	196.00	228.55	34.88	8.54	0.94	77.99
Total	All	2008	259.13	106.46	240.47	309.09	378.52	64.11	12.74	2.74	197.40
Age*	Under 65	2008	47.60	13.37	32.85	50.93	59.73	13.10	3.12	0.36	27.49
	65 to 74	2008	88.88	35.52	76.69	88.93	123.50	20.99	3.51	0.96	78.43
	75 to 84	2008	78.30	36.88	81.09	96.05	123.37	20.07	3.78	0.99	64.24
	85 and older	2008	44.37	20.70	49.84	73.18	71.92	9.95	2.34	0.42	27.24
Gender	Male	2008	102.83	31.59	74.96	97.60	136.37	34.45	5.17	1.04	58.61
	Female	2008	156.31	74.87	165.51	211.48	242.15	29.66	7.57	1.70	138.79
Race	White	2008	211.57	84.13	183.87	253.72	314.39	47.46	7.57	2.11	155.87
	Black	2008	31.34	11.90	38.89	40.93	41.07	12.36	4.34	0.34	28.68
	Other	2008	3.02	1.90	3.33	2.72	4.59	0.82	0.16	0.05	2.58
	Asian	2008	4.02	4.66	7.07	3.63	7.81	1.47	0.24	0.13	4.89
	Hispanic	2008	7.41	3.39	6.28	6.40	8.94	1.67	0.38	0.09	4.89
	American Indian/Alaska Native	2008	1.77	0.48	1.04	1.69	1.70	0.34	0.05	0.01	0.48
Comorbid Condition	Diabetes	2008	125.28	50.48	100.35	146.55	160.07	30.26	7.62	1.46	76.91
	Cancer	2008	49.94	22.57	50.29	62.43	79.57	13.44	2.43	0.62	38.45
	Osteoporosis	2008	34.30	18.16	38.33	45.87	55.78	6.54	1.41	0.47	28.78
	Osteoarthritis	2008	92.89	43.18	94.51	129.00	142.14	23.68	4.97	1.19	75.88
	Hyperlipidemic	2008	181.54	77.98	164.00	200.34	269.59	42.37	8.76	2.21	141.73
	Cardiovascular disease	2008	142.04	58.93	127.41	195.34	237.35	34.80	9.61	1.84	76.10
Total	All	2009	254.12	102.59	242.23	297.98	370.97	62.26	14.36	3.81	185.05

			Number of Prescriptions (in 100,000s)								
Breakdown	Category	Year	ACE Inhibitor	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vaso-dilators	Other Renin Angiotensin Antagonists	Combined Therapy
Age*	Under 65	2009	48.66	12.95	34.13	50.76	60.42	13.44	3.51	0.51	26.79
	65 to 74	2009	86.24	33.93	77.37	84.52	119.50	19.93	3.96	1.32	73.09
	75 to 84	2009	75.14	35.08	80.01	90.74	118.49	19.07	4.22	1.36	59.27
	85 and older	2009	44.08	20.64	50.72	71.96	72.55	9.81	2.67	0.62	25.89
Gender	Male	2009	101.96	30.66	77.34	95.46	135.22	33.56	5.79	1.38	55.88
	Female	2009	152.17	71.92	164.88	202.52	235.75	28.70	8.57	2.43	129.17
Race	White	2009	205.28	79.99	183.31	242.18	305.20	45.47	8.41	2.87	144.16
	Black	2009	32.03	11.83	40.46	40.99	41.87	12.42	4.97	0.51	28.03
	Other	2009	3.14	1.99	3.51	2.80	4.81	0.85	0.19	0.08	2.62
	Asian	2009	4.08	4.81	7.21	3.66	8.02	1.45	0.28	0.20	4.82
	Hispanic	2009	7.78	3.51	6.60	6.63	9.31	1.73	0.46	0.14	4.95
	American Indian/Alaska Native	2009	1.80	0.47	1.12	1.72	1.77	0.35	0.06	0.01	0.47
Comorbid Condition	Diabetes	2009	124.06	49.50	103.58	144.18	160.39	30.14	8.78	2.09	73.79
	Cancer	2009	49.51	22.09	51.29	61.10	78.97	13.19	2.79	0.85	36.60
	Osteoporosis	2009	34.42	18.00	39.16	45.08	55.83	6.52	1.64	0.67	27.51
	Osteoarthritis	2009	92.90	42.43	96.35	126.93	141.84	23.45	5.76	1.69	72.37
	Hyperlipidemic	2009	181.48	76.57	169.47	198.32	269.08	42.22	10.20	3.09	135.21
	Cardiovascular disease	2009	138.31	56.77	127.99	189.83	232.55	34.13	10.87	2.47	71.02

Table 14. Total Drug Cost and Out-of-Pocket Cost, by Antihypertensive Drug Class, Among Medicare Parts A, B, and D Beneficiaries With Hypertension, 2006-2009

Note: Age is calculated as of December 31 of the year. Note: An asterisk (*) signifies small cell count (<11).

Breakdown	Category	Year	Total Expenditure per Antihypertensive Medication (in \$100,000s)																	
			ACE Inhibitors		Angiotensin II Receptor Antagonists		Calcium Channel Blockers		Diuretics		Beta Blockers		Anti-Adrenergic Agents		Vasodilators		Other Renin Angiotensin Antagonists		Combined Therapy	
			Total Drug Cost	Total Out-of-Pocket Pay-ment	Total Drug Cost	Total Out-of-Pocket Pay-ment	Total Drug Cost	Total Out-of-Pocket Pay-ment	Total Drug Cost	Total Out-of-Pocket Pay-ment	Total Drug Cost	Total Out-of-Pocket Pay-ment	Total Drug Cost	Total Out-of-Pocket Pay-ment	Total Drug Cost	Total Out-of-Pocket Pay-ment	Total Drug Cost	Total Out-of-Pocket Pay-ment	Total Drug Cost	Total Out-of-Pocket Pay-ment
Total	All	2006	3,264	1,665	4,439	2,591	7,943	4,014	1,474	869	5,784	3,312	979	487	208	88	45	23	5,874	3,168
Age*	Under 65	2006	563	288	620	351	1,199	603	273	148	955	520	202	99	56	24	7	3	863	467
	65to 74	2006	1,156	583	1,527	887	2,569	1,272	417	246	1,923	1,102	299	147	58	24	16	8	2,349	1,248
	75to 84	2006	1,040	533	1,555	915	2,711	1,374	460	278	1,939	1,123	311	156	62	26	16	8	1,969	1,069
	85and older	2006	506	261	738	439	1,465	765	324	197	966	567	167	86	33	14	6	3	694	383
Gender	Male	2006	1,254	635	1,274	734	2,418	1,188	446	257	2,146	1,188	418	201	84	35	28	14	1,763	925
	Female	2006	2,010	1,030	3,164	1,857	5,525	2,827	1,028	612	3,638	2,124	561	286	124	53	18	9	4,111	2,243
Race	White	2006	2,606	1,326	3,345	1,929	5,639	2,797	1,171	690	4,512	2,584	649	320	117	48	38	20	4,273	2,270
	Black	2006	435	221	585	342	1,564	802	231	135	819	457	256	130	78	34	4	2	1,035	562
	Other	2006	37	19	76	47	118	63	12	7	75	44	13	6	2	1	1	0	87	50
	Asian	2006	58	31	237	152	315	181	18	11	148	91	24	12	4	2	1	0	227	138
	Hispanic	2006	109	58	177	111	275	154	36	22	207	124	32	16	6	3	1	1	240	141
	American Indian/ Alaska Native	2006	20	10	18	11	32	17	7	4	23	13	5	2	1	0	*	*	14	7
Comorbid Condition	Diabetes	2006	1,669	860	2,211	1,299	3,525	1,818	812	465	2,889	1,620	517	258	127	55	25	13	2,619	1,437
	Cancer	2006	618	315	879	508	1,547	768	277	164	1,162	663	189	93	37	15	12	6	1,064	567
	Osteoporosis	2006	431	224	734	434	1,230	640	211	127	814	479	115	58	22	9	5	3	891	494
	Osteoarthritis	2006	1,216	627	1,876	1,101	3,244	1,670	659	386	2,305	1,327	380	191	80	34	17	9	2,450	1,344
	Hyper-lipidemia	2006	2,329	1,193	3,231	1,891	5,351	2,710	916	545	4,246	2,436	605	301	134	57	37	19	4,392	2,374
	Cardio-vascular disease	2006	1,953	1,015	2,562	1,508	4,463	2,308	1,054	611	4,321	2,426	628	316	163	70	41	21	2,679	1,472
Total	All	2007	4,800	2,452	7,569	4,487	11,038	4,464	2,123	1,211	9,345	4,835	1,377	684	334	125	122	70	10,470	5,233
Age*	Under 65	2007	703	352	877	508	1,415	609	352	178	1,348	690	260	125	83	32	16	9	1,311	671
	65to 74	2007	1,747	882	2,609	1,531	3,618	1,404	618	352	3,129	1,609	420	205	95	35	44	25	4,253	2,088
	75to 84	2007	1,575	813	2,714	1,619	3,850	1,550	677	398	3,203	1,664	445	223	100	37	44	26	3,564	1,794
	85and older	2007	775	405	1,369	829	2,155	900	476	283	1,664	871	251	131	56	21	17	11	1,342	680
Gender	Male	2007	1,922	978	2,217	1,299	3,446	1,337	677	378	3,551	1,778	592	283	137	50	65	36	3,252	1,565
	Female	2007	2,878	1,474	5,352	3,188	7,592	3,127	1,445	834	5,794	3,056	784	401	196	75	57	34	7,218	3,668
Race	White	2007	4,000	2,051	6,029	3,554	8,340	3,290	1,745	1,005	7,587	3,912	959	475	196	72	101	58	8,084	3,995
	Black	2007	523	258	814	489	1,853	783	286	154	1,131	586	325	164	117	44	12	7	1,559	791
	Other	2007	54	27	132	76	159	67	17	10	120	61	17	8	4	2	2	1	157	79
	Asian	2007	70	37	329	204	347	165	22	13	206	112	29	14	6	2	4	2	325	181
	Hispanic	2007	122	64	235	146	294	138	42	24	261	143	38	20	9	4	3	2	323	176

			Total Expenditure per Antihypertensive Medication (in \$100,000s)																	
			ACE Inhibitors		Angiotensin II Receptor Antagonists		Calcium Channel Blockers		Diuretics		Beta Blockers		Anti-Adrenergic Agents		Vasodilators		Other Renin Angiotensin Antagonists		Combined Therapy	
Breakdown	Category	Year	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment
	American Indian/Alaska Native	2007	31	15	30	18	45	21	11	6	39	20	7	4	1	1	0	0	21	11
Comorbid Condition	Diabetes	2007	2,331	1,198	3,573	2,139	4,685	1,988	1,122	620	4,482	2,336	715	356	201	78	65	36	4,466	2,303
	Cancer	2007	991	511	1,627	959	2,335	925	431	250	2,002	1,028	286	141	63	23	31	17	2,038	1,015
	Osteoporosis	2007	635	332	1,268	760	1,723	728	305	180	1,308	696	165	84	35	13	17	10	1,555	803
	Osteoarthritis	2007	1,720	886	3,076	1,834	4,342	1,814	922	521	3,602	1,888	531	266	126	48	48	27	4,115	2,103
	Hyper-lipidemia	2007	3,566	1,830	5,658	3,361	7,749	3,131	1,401	808	7,064	3,665	900	447	227	86	101	58	8,009	4,028
	Cardio-vascular disease	2007	2,790	1,464	4,212	2,527	5,957	2,515	1,464	823	6,807	3,486	862	434	255	98	96	54	4,575	2,355
Total	All	2008	4,327	1,984	8,599	4,959	7,789	2,915	2,153	1,218	6,964	3,074	1,440	712	372	141	266	142	11,169	5,262
Age*	Under 65	2008	635	308	981	546	1,001	406	357	184	963	437	283	136	92	36	33	17	1,359	662
	65to 74	2008	1,582	694	2,968	1,692	2,608	920	632	352	2,373	1,010	432	208	106	39	96	51	4,583	2,102
	75to 84	2008	1,393	640	3,042	1,769	2,682	1,003	675	393	2,369	1,052	455	227	110	41	97	52	3,767	1,795
	85and older	2008	717	342	1,608	952	1,498	586	489	290	1,260	576	269	140	64	24	40	22	1,460	703
Gender	Male	2008	1,758	783	2,569	1,463	2,470	876	702	387	2,531	1,087	610	288	154	56	110	57	3,529	1,584
	Female	2008	2,569	1,201	6,030	3,496	5,319	2,039	1,451	831	4,433	1,987	831	424	219	84	156	85	7,641	3,678
Race	White	2008	3,600	1,636	6,839	3,930	5,927	2,162	1,773	1,007	5,713	2,496	994	487	218	80	210	112	8,638	4,005
	Black	2008	473	227	912	526	1,304	523	286	158	782	360	348	176	130	51	31	17	1,626	790
	Other	2008	52	24	160	88	114	43	19	10	97	42	19	9	5	2	5	3	180	85
	Asian	2008	66	32	389	234	225	94	23	13	167	80	31	15	7	3	12	6	373	199
	Hispanic	2008	108	52	263	159	187	79	41	23	177	83	40	21	11	4	8	4	330	172
	American Indian/Alaska Native	2008	29	14	35	21	32	14	11	6	29	14	7	4	2	1	1	0	22	11
Comorbid Condition	Diabetes	2008	2,114	983	4,111	2,397	3,360	1,310	1,147	631	3,182	1,435	770	380	230	90	143	76	4,844	2,368
	Cancer	2008	918	414	1,905	1,096	1,703	621	451	257	1,550	676	303	146	72	27	63	33	2,253	1,052
	Osteoporosis	2008	600	281	1,502	876	1,255	486	322	187	1,065	481	183	92	41	16	44	23	1,728	841
	Osteoarthritis	2008	1,575	734	3,518	2,042	3,087	1,192	949	533	2,709	1,215	565	281	146	56	114	60	4,431	2,141
	Hyper-lipidemia	2008	3,268	1,481	6,563	3,794	5,624	2,094	1,468	834	5,349	2,352	970	476	263	100	219	117	8,707	4,129
	Cardio-vascular disease	2008	2,490	1,152	4,778	2,796	4,158	1,618	1,480	826	4,668	2,079	913	456	286	110	183	98	4,842	2,363
Total	All	2009	3,495	1,738	9,356	5,411	7,226	2,908	2,159	1,263	7,458	3,477	1,459	741	422	168	387	195	11,398	5,659
Age*	Under 65	2009	537	283	1,060	590	936	417	363	196	1,018	498	302	150	103	43	49	24	1,383	712
	65to 74	2009	1,276	604	3,217	1,845	2,442	927	635	362	2,577	1,146	427	212	121	47	139	69	4,670	2,256
	75to 84	2009	1,098	545	3,274	1,907	2,453	978	666	398	2,501	1,166	448	230	124	49	139	70	3,815	1,908
	85and older	2009	583	305	1,805	1,069	1,395	586	495	306	1,362	668	283	149	73	30	61	32	1,530	784
Gender	Male	2009	1,422	687	2,826	1,616	2,334	901	718	410	2,734	1,239	606	302	173	67	148	71	3,630	1,731

			Total Expenditure per Antihypertensive Medication (in \$100,000s)																	
			ACE Inhibitors		Angiotensin II Receptor Antagonists		Calcium Channel Blockers		Diuretics		Beta Blockers		Anti-Adrenergic Agents		Vasodilators		Other Renin Angiotensin Antagonists		Combined Therapy	
Breakdown	Category	Year	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment	Total Drug Cost	Total Out-of-Pocket Payment
	Female	2009	2,072	1,051	6,530	3,794	4,892	2,007	1,441	853	4,724	2,239	854	439	249	101	239	125	7,769	3,927
Race	White	2009	2,879	1,417	7,377	4,272	5,507	2,143	1,772	1,038	6,142	2,816	986	496	246	95	298	149	8,724	4,272
	Black	2009	400	209	1,008	579	1,204	529	289	167	808	405	371	192	147	61	48	25	1,689	868
	Other	2009	45	22	186	101	110	46	20	12	110	51	20	10	6	2	8	4	201	98
	Asian	2009	56	29	446	260	204	95	24	15	181	93	32	16	8	4	19	10	406	219
	Hispanic	2009	90	48	301	176	172	82	43	25	185	96	42	22	13	6	13	7	356	191
	American Indian/Alaska Native	2009	24	13	38	23	30	14	11	7	31	16	8	4	2	1	1	0	23	12
Comorbid Condition	Diabetes	2009	1,721	857	4,528	2,630	3,165	1,323	1,164	663	3,386	1,622	801	405	265	109	213	108	5,040	2,567
	Cancer	2009	749	363	2,114	1,223	1,622	628	463	272	1,701	777	307	152	84	32	91	45	2,356	1,158
	Osteoporosis	2009	492	249	1,674	974	1,185	488	329	197	1,171	559	190	96	48	20	67	34	1,816	921
	Osteoarthritis	2009	1,290	647	3,885	2,252	2,891	1,193	964	559	2,923	1,389	584	296	169	69	169	85	4,602	2,324
	Hyper-lipidemia	2009	2,672	1,305	7,269	4,207	5,345	2,129	1,515	884	5,838	2,703	1,006	507	309	123	321	162	9,019	4,487
	Cardio-vascular disease	2009	1,950	972	5,175	3,026	3,831	1,597	1,489	861	4,880	2,313	937	477	324	132	253	127	4,908	2,503

Table 15. Total Drug Cost, by Antihypertensive Drug Class, Among Medicare Parts A, B, and D Beneficiaries With Hypertension, by Hospital Referral Region, 2009

Year	HRR	Total Medication Cost per Antihypertensive Medication Class (in \$)								
		ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin Angiotensin Antagonists	Combined Therapy
2009	1	446,444	826,600	689,937	220,576	738,667	149,073	70,986	31,204	1,612,582
2009	2	83,294	186,749	166,561	52,826	157,180	42,756	14,027	7,799	361,421
2009	5	106,136	220,675	181,264	52,459	188,278	38,223	9,432	7,712	427,140
2009	6	135,776	263,870	245,780	65,930	249,478	49,428	25,000	12,433	593,120
2009	7	69,163	124,125	132,643	36,083	102,951	24,227	14,649	6,025	261,514
2009	9	56,730	93,584	87,559	32,636	77,183	17,275	5,919	2,012	180,825
2009	10	68,991	186,831	93,626	26,226	120,190	28,399	3,142	10,865	206,818
2009	11	87,727	213,529	138,654	27,014	132,281	21,975	6,315	6,147	269,497
2009	12	394,644	812,622	559,140	120,464	548,352	94,497	28,305	27,389	983,864
2009	14	59,566	172,422	117,009	17,649	108,224	23,369	8,437	4,205	155,118
2009	15	117,472	303,713	189,341	42,367	168,944	33,101	8,908	14,672	296,171
2009	16	75,276	149,050	132,226	40,746	146,298	25,998	2,571	4,765	283,411
2009	18	56,420	108,468	102,669	32,245	82,140	21,102	4,179	3,363	248,997
2009	19	295,806	623,013	610,396	157,894	563,222	131,649	29,021	23,784	1,379,159
2009	21	62,016	155,113	118,118	31,839	119,458	19,816	3,898	5,339	292,664
2009	22	57,006	115,530	90,839	30,486	97,583	29,668	5,412	3,037	241,268
2009	23	316,034	1,233,809	555,613	102,288	634,919	169,403	19,967	60,553	1,368,591
2009	25	172,125	478,927	227,414	60,622	247,590	46,916	8,693	22,449	537,818
2009	31	86,425	214,483	116,780	37,016	123,865	24,405	3,348	8,545	247,808
2009	33	101,213	308,448	178,479	37,109	166,902	41,072	8,441	8,731	256,733
2009	43	174,841	476,250	239,103	65,586	321,185	41,857	15,659	19,437	739,902
2009	56	984,292	4,484,254	1,973,256	356,211	2,115,392	498,399	115,769	239,725	5,475,633
2009	58	165,321	364,250	194,906	57,074	205,348	41,888	8,008	9,123	418,161
2009	62	66,304	142,634	85,519	21,686	103,818	19,068	3,117	3,813	146,001
2009	65	143,934	563,211	329,833	57,796	259,301	81,116	23,541	12,535	452,146
2009	69	78,040	260,097	115,970	25,272	145,952	27,952	3,430	13,446	283,849
2009	73	93,963	211,118	130,767	35,741	123,358	32,921	3,558	3,118	255,683
2009	77	293,510	786,196	478,980	106,794	434,445	91,756	33,183	25,302	903,837
2009	78	69,813	205,829	115,098	24,325	108,642	30,617	9,189	6,382	263,755
2009	79	220,837	560,868	346,970	76,440	300,518	92,646	15,925	21,934	622,169
2009	80	323,951	1,151,456	560,116	122,267	583,453	111,885	26,336	57,388	1,294,759
2009	81	199,400	743,805	375,391	68,352	354,806	101,405	24,376	20,507	551,891
2009	82	202,617	888,698	410,173	60,898	380,970	87,741	17,793	30,531	937,605
2009	83	55,993	149,307	81,573	18,043	87,369	14,113	1,927	4,505	124,601

		Total Medication Cost per Antihypertensive Medication Class (in \$)								
Year	HRR	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin Angiotensin Antagonists	Combined Therapy
2009	85	66,742	276,885	137,572	28,019	126,172	29,048	6,497	10,228	231,387
2009	86	80,250	223,983	113,102	29,106	109,803	23,138	5,950	9,539	237,209
2009	87	49,649	118,731	71,938	17,650	57,751	19,348	2,585	2,441	96,167
2009	89	69,534	167,735	89,717	24,791	90,345	18,951	2,770	8,528	158,765
2009	91	93,998	209,909	131,214	30,946	148,860	22,300	8,274	8,432	221,867
2009	96	118,003	379,072	181,732	40,474	210,456	54,301	14,532	16,603	459,116
2009	101	18,572	53,867	27,173	6,585	28,990	4,890	1,333	-	53,700
2009	102	78,152	155,151	126,143	34,732	109,174	29,392	3,733	5,629	198,028
2009	103	190,062	441,539	272,941	80,933	286,545	54,147	17,276	16,109	539,993
2009	104	42,752	94,704	57,391	18,043	63,947	12,009	3,326	2,194	123,120
2009	105	30,032	60,284	42,815	12,569	50,821	9,064	1,264	1,184	78,297
2009	106	59,675	104,247	63,972	22,650	79,178	13,787	3,486	1,947	136,935
2009	107	25,947	47,811	41,362	12,748	33,384	9,529	1,650	1,030	59,788
2009	109	119,298	328,330	192,221	39,537	252,442	24,288	7,355	10,559	452,862
2009	110	336,099	774,231	535,478	130,334	623,523	67,791	22,760	32,594	1,001,236
2009	111	315,663	773,125	528,745	120,532	610,521	69,830	22,473	25,152	955,482
2009	112	240,893	545,760	448,463	84,873	416,605	94,494	23,675	20,574	843,260
2009	113	374,189	1,012,953	732,692	148,039	718,553	174,235	55,751	32,115	1,543,300
2009	115	55,847	157,763	107,881	23,738	106,366	22,318	4,413	7,191	258,946
2009	116	94,798	219,661	149,458	35,820	167,200	30,642	4,653	7,187	284,636
2009	118	500,789	1,602,075	969,754	197,458	1,060,650	170,380	37,193	74,102	2,024,879
2009	119	337,349	842,972	536,133	114,374	633,482	79,795	17,551	41,079	1,319,964
2009	120	125,731	232,494	202,776	51,029	184,294	43,228	9,240	8,456	371,669
2009	122	80,817	159,709	125,526	29,009	134,597	28,496	2,533	5,095	202,451
2009	123	305,689	643,084	502,685	127,536	477,473	128,804	40,230	21,783	987,780
2009	124	56,692	124,747	97,235	21,146	99,964	17,478	4,379	5,338	190,548
2009	127	331,143	1,107,697	627,289	137,557	767,131	168,547	29,440	60,206	1,627,019
2009	129	218,626	432,846	322,929	65,351	329,657	52,589	13,376	20,242	658,448
2009	130	595,641	1,386,240	1,059,820	232,504	1,120,654	218,388	63,412	54,259	2,175,822
2009	131	81,395	185,665	122,955	31,017	140,719	21,709	4,201	6,610	272,741
2009	133	50,892	126,847	58,683	18,510	109,265	20,124	2,115	6,131	186,643
2009	134	128,004	276,812	193,343	62,579	235,584	64,479	9,631	13,829	461,610
2009	137	174,140	446,712	266,035	59,338	322,888	45,691	4,259	19,333	646,647
2009	139	76,045	188,916	120,186	28,378	118,459	26,055	5,921	8,568	226,748
2009	140	124,175	292,027	236,002	65,154	222,940	66,947	16,942	11,716	541,608
2009	141	142,700	363,192	275,180	56,188	245,865	60,525	15,988	13,345	566,958

		Total Medication Cost per Antihypertensive Medication Class (in \$)								
Year	HRR	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin Angiotensin Antagonists	Combined Therapy
2009	142	34,874	81,608	88,917	23,097	49,941	21,497	15,119	2,137	170,953
2009	144	791,985	1,797,833	1,682,857	353,362	1,428,017	359,122	149,801	62,972	3,146,334
2009	145	121,326	272,596	242,022	60,422	205,784	50,569	19,236	17,182	560,452
2009	146	57,331	111,898	131,141	34,024	86,282	33,154	8,011	6,141	230,089
2009	147	128,122	316,134	272,283	75,255	245,017	72,505	23,746	15,377	620,945
2009	148	73,739	112,321	137,777	36,539	115,972	22,274	7,900	6,064	300,585
2009	149	148,332	374,458	270,615	74,137	269,261	48,744	17,234	16,818	781,111
2009	150	170,191	749,499	392,790	50,548	387,683	57,858	13,555	22,320	817,903
2009	151	107,241	234,116	142,191	47,964	150,914	27,298	3,339	8,174	276,230
2009	152	39,635	67,034	40,999	13,917	47,101	11,917	905	1,480	127,183
2009	154	32,773	82,816	61,375	15,431	63,730	13,253	2,880	1,577	109,097
2009	155	171,905	397,694	395,424	77,854	376,233	71,231	36,824	14,814	698,500
2009	156	368,125	907,440	919,034	175,401	733,590	192,831	108,650	22,636	1,306,371
2009	158	122,642	306,357	262,052	53,294	308,411	39,558	14,672	9,615	536,468
2009	161	251,440	677,468	462,084	95,350	537,491	63,435	23,058	30,003	909,770
2009	163	79,491	216,180	151,731	34,920	175,268	30,223	11,236	6,346	325,743
2009	164	113,143	279,283	246,543	58,436	244,239	45,940	14,082	8,301	487,765
2009	166	217,830	572,875	471,829	100,146	498,552	83,540	33,491	15,967	892,724
2009	170	120,781	229,604	200,784	56,476	186,170	38,197	10,085	8,923	311,688
2009	171	164,478	284,020	263,079	64,932	250,094	53,239	22,931	7,218	367,878
2009	172	218,096	439,476	413,452	115,138	450,351	66,579	17,387	16,358	599,841
2009	173	69,113	149,031	126,718	36,739	128,182	27,784	4,607	3,869	237,627
2009	175	26,335	61,572	46,803	10,633	50,543	8,563	1,241	3,744	81,401
2009	179	165,887	346,825	280,465	85,278	283,728	64,889	14,393	18,882	525,404
2009	180	123,047	302,054	252,226	68,225	254,723	51,307	11,540	7,740	575,395
2009	181	123,406	252,233	207,058	50,272	184,747	38,722	13,123	12,062	485,259
2009	183	553,294	1,213,122	1,035,538	255,074	1,072,954	206,254	58,910	48,476	2,011,568
2009	184	43,943	85,541	76,266	21,129	81,256	16,907	4,913	1,093	123,995
2009	185	37,651	75,583	74,641	25,814	75,398	14,752	5,020	4,830	154,614
2009	186	67,474	149,429	127,980	28,939	120,971	26,072	9,837	4,698	269,241
2009	187	153,726	313,839	239,559	67,178	229,751	54,117	9,588	10,272	525,740
2009	188	44,643	83,947	83,966	23,339	96,814	17,053	4,439	4,817	168,635
2009	190	57,204	115,062	109,299	28,407	98,498	11,321	3,075	1,668	136,873
2009	191	99,495	203,117	165,832	45,837	164,542	25,436	8,634	4,779	262,305
2009	192	188,402	457,986	346,155	104,855	361,348	67,678	13,772	13,440	805,426
2009	193	17,492	37,925	29,908	8,319	27,418	4,622	788	-	39,491

		Total Medication Cost per Antihypertensive Medication Class (in \$)								
Year	HRR	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin Angiotensin Antagonists	Combined Therapy
2009	194	62,305	127,671	103,200	34,065	99,118	17,111	5,309	2,048	140,749
2009	195	41,613	92,835	61,968	24,083	72,655	6,296	4,511	2,147	121,883
2009	196	50,450	110,790	101,379	27,142	87,819	13,185	2,904	5,359	194,490
2009	197	41,104	85,712	77,763	24,141	69,445	11,795	7,925	1,665	115,267
2009	200	95,793	230,255	155,744	45,085	153,333	34,070	3,279	9,505	308,111
2009	201	263,390	644,390	532,813	164,355	453,478	99,493	16,215	28,333	1,196,815
2009	203	62,283	116,689	114,011	28,938	108,605	21,909	8,104	5,987	189,123
2009	204	372,001	644,232	595,423	158,004	581,096	101,161	33,794	54,294	1,022,512
2009	205	315,215	633,559	615,641	160,225	610,436	92,789	55,788	39,177	1,206,862
2009	207	42,372	94,664	70,984	17,881	58,416	13,560	2,705	5,299	119,099
2009	208	125,819	242,634	173,919	52,876	191,279	36,072	7,662	14,107	325,108
2009	209	63,163	158,681	143,118	36,077	125,995	38,906	6,609	9,576	299,796
2009	210	101,409	239,706	234,095	56,890	196,902	75,621	20,824	7,878	498,424
2009	212	68,237	140,632	115,798	26,894	136,977	23,473	5,022	8,301	278,726
2009	213	129,441	300,192	243,593	65,515	278,167	77,641	15,370	13,763	767,655
2009	214	57,896	102,684	92,582	22,336	93,225	17,599	4,730	4,039	235,879
2009	216	61,013	131,669	104,078	28,081	105,954	39,617	6,837	5,508	224,890
2009	217	61,196	136,087	126,168	34,211	121,556	37,168	7,084	7,019	300,213
2009	218	63,014	157,306	137,327	32,545	112,476	45,843	15,188	8,399	282,258
2009	219	126,369	282,693	290,232	67,980	222,927	72,539	22,005	8,498	520,073
2009	220	28,005	61,050	44,883	12,937	46,805	12,884	2,778	2,069	116,643
2009	221	147,781	293,575	197,320	58,538	203,426	42,860	9,982	8,392	237,881
2009	222	295,785	645,522	429,360	123,230	458,875	76,098	26,592	7,995	467,140
2009	223	503,779	1,352,978	1,191,154	206,096	1,101,173	186,847	60,682	60,606	2,221,606
2009	225	173,774	414,558	315,211	64,623	337,890	52,403	16,156	10,645	627,793
2009	226	86,362	313,793	222,081	36,578	218,964	44,723	12,528	8,024	531,527
2009	227	874,768	1,916,315	1,573,338	353,467	1,363,118	293,469	63,696	28,516	1,239,621
2009	230	130,847	325,418	258,866	59,176	222,774	53,892	7,924	7,575	259,260
2009	231	102,587	191,285	151,980	40,578	145,867	24,101	6,638	2,745	129,000
2009	232	206,368	351,917	343,050	84,123	346,619	71,435	27,723	10,702	519,364
2009	233	93,458	136,976	147,553	33,947	146,974	29,763	14,223	6,684	231,505
2009	234	351,956	531,320	671,978	143,728	533,784	139,842	105,441	24,138	908,125
2009	235	102,819	132,007	163,296	39,877	153,704	37,017	9,460	6,133	235,103
2009	236	156,925	260,099	253,697	62,977	248,421	42,260	25,118	7,571	372,708
2009	238	115,713	209,614	184,795	58,233	207,825	47,039	18,304	2,936	334,981
2009	239	104,262	168,764	175,487	49,062	174,552	51,786	7,709	4,776	249,278

		Total Medication Cost per Antihypertensive Medication Class (in \$)								
Year	HRR	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin Angiotensin Antagonists	Combined Therapy
2009	240	42,728	82,415	70,594	21,037	70,531	12,039	1,605	2,311	111,564
2009	242	51,712	83,416	89,711	23,153	73,664	16,125	2,472	3,163	119,435
2009	243	44,634	90,255	70,808	18,358	79,575	15,619	2,540	1,560	123,468
2009	244	71,241	142,326	125,672	28,113	127,416	23,720	10,387	5,938	227,213
2009	245	136,900	311,950	236,066	49,967	284,187	45,510	24,190	20,773	463,337
2009	246	166,949	257,652	266,334	74,227	256,968	48,209	14,457	10,508	374,289
2009	248	36,548	93,729	67,735	17,538	69,384	12,752	4,256	1,684	165,086
2009	249	68,068	115,433	100,692	28,054	107,243	17,148	3,687	5,082	175,376
2009	250	66,174	186,938	87,273	29,795	105,606	13,691	2,683	730	116,883
2009	251	334,670	933,567	525,364	152,293	587,076	97,770	35,402	9,845	796,143
2009	253	68,691	179,485	105,745	34,211	111,819	17,356	4,811	2,473	119,250
2009	254	33,643	90,418	49,322	14,127	51,591	7,516	2,417	682	87,531
2009	256	81,468	229,925	124,593	39,572	129,645	38,087	12,021	2,002	165,213
2009	257	30,968	70,542	56,719	16,595	44,192	12,107	3,076	3,693	149,377
2009	258	65,436	179,730	129,165	39,533	139,074	28,354	12,863	5,307	408,440
2009	259	203,598	480,700	478,748	143,782	387,498	104,443	38,958	13,724	1,311,139
2009	260	41,654	86,548	115,392	32,111	83,522	23,348	9,784	2,149	241,148
2009	261	31,846	87,577	68,471	24,019	60,702	16,189	7,478	2,087	207,266
2009	262	112,641	228,413	176,189	58,292	205,683	38,038	13,176	8,250	536,301
2009	263	75,670	153,530	123,438	47,127	134,923	27,787	13,377	8,219	295,814
2009	264	185,483	324,308	300,068	86,147	272,317	48,347	8,749	9,086	491,310
2009	267	98,365	214,133	166,697	48,351	163,477	36,541	5,247	10,552	315,687
2009	268	424,706	839,911	724,665	182,705	667,747	157,769	34,286	29,369	1,204,845
2009	270	170,793	333,146	282,603	80,745	272,850	57,601	11,522	17,794	443,593
2009	273	684,382	1,350,270	1,220,465	307,136	1,088,881	217,554	112,372	45,962	1,891,264
2009	274	92,627	229,981	131,863	48,386	153,642	23,193	2,532	7,118	306,372
2009	275	24,059	80,334	34,453	13,267	45,169	7,240	940	1,347	92,599
2009	276	70,089	165,337	86,005	32,212	107,824	17,982	2,283	3,127	165,995
2009	277	120,981	288,440	174,311	61,822	243,330	32,042	7,857	11,674	429,620
2009	278	223,865	485,290	370,090	113,005	449,918	75,190	21,348	16,583	761,691
2009	279	179,464	409,680	302,549	67,342	283,104	55,797	27,682	25,866	604,300
2009	280	108,694	242,876	144,334	42,072	144,098	27,897	3,900	7,214	291,722
2009	281	116,030	254,843	177,324	49,567	216,129	28,964	3,726	1,675	173,230
2009	282	176,402	370,976	268,161	67,868	303,139	40,550	5,881	6,526	351,486
2009	283	862,792	2,206,794	1,546,456	300,591	1,794,088	248,016	73,063	112,046	3,181,298
2009	284	297,312	906,369	494,299	97,557	739,211	79,785	12,516	60,034	1,397,041


		Total Medication Cost per Antihypertensive Medication Class (in \$)								
Year	HRR	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin Angiotensin Antagonists	Combined Therapy
2009	285	202,238	577,162	381,471	76,915	484,389	56,037	8,753	29,800	1,045,506
2009	288	241,545	612,204	425,567	79,767	506,871	89,645	11,776	25,978	924,973
2009	289	248,796	783,318	544,833	106,426	669,740	99,995	21,592	56,342	1,543,889
2009	291	96,235	242,167	161,835	33,654	181,581	27,848	5,782	10,358	429,531
2009	292	98,953	267,420	152,703	36,900	205,493	20,841	3,266	17,906	385,852
2009	293	290,405	506,373	355,929	87,763	353,169	79,936	14,997	11,871	514,313
2009	295	351,507	703,601	501,382	130,402	632,399	97,088	23,232	25,875	854,030
2009	296	104,923	233,392	139,448	37,689	189,345	23,113	3,232	9,904	298,991
2009	297	120,594	271,295	254,512	47,880	237,547	45,572	18,430	10,819	413,968
2009	299	132,983	257,378	217,380	55,915	219,745	55,178	18,225	7,458	350,876
2009	300	104,451	204,213	118,289	36,225	170,435	21,403	7,194	5,582	213,748
2009	301	985,493	2,459,779	1,557,667	297,083	1,965,413	232,509	75,410	101,349	3,274,896
2009	303	730,085	2,333,450	1,400,433	257,793	1,708,832	227,646	64,143	124,301	3,185,228
2009	304	125,734	273,453	204,734	54,298	219,532	39,416	14,358	10,322	272,147
2009	307	222,157	506,191	326,454	88,959	365,663	65,111	7,897	13,748	588,485
2009	308	241,710	557,962	351,445	75,555	496,167	58,194	9,941	23,913	715,163
2009	309	167,418	352,996	261,845	75,111	276,037	59,059	6,279	11,149	533,417
2009	311	427,793	897,319	818,856	199,016	749,439	182,930	42,962	39,154	1,856,045
2009	312	329,596	569,572	484,668	130,751	468,021	110,752	40,848	16,638	1,042,211
2009	313	91,327	175,298	153,857	41,914	153,915	36,260	9,036	9,189	321,929
2009	314	181,222	406,158	380,224	99,710	309,839	99,927	35,097	16,634	858,824
2009	315	66,360	144,368	122,737	32,736	109,705	20,530	5,988	4,733	299,020
2009	318	295,368	618,358	539,410	152,968	531,130	138,694	46,508	32,733	1,345,406
2009	319	111,131	251,465	179,937	52,893	208,114	50,419	13,810	19,029	574,652
2009	320	210,578	383,363	314,768	94,121	349,327	65,408	21,779	11,406	629,619
2009	321	71,493	146,861	93,163	34,492	118,560	15,251	1,915	2,471	188,618
2009	322	107,444	264,686	169,813	50,291	194,371	26,928	8,804	4,274	329,599
2009	323	46,234	95,071	64,343	20,951	65,892	7,785	2,023	1,371	113,046
2009	324	48,221	79,950	44,077	22,486	58,126	7,590	1,820	-	92,688
2009	325	75,590	141,850	128,465	34,134	106,697	34,001	11,315	5,981	194,427
2009	326	82,902	193,800	129,144	39,981	134,343	27,328	7,771	11,367	252,645
2009	327	202,789	416,366	400,522	107,073	316,076	85,147	21,199	23,256	655,431
2009	328	346,632	703,189	582,039	151,603	583,289	137,466	55,893	19,453	884,920
2009	329	443,867	901,420	751,418	194,882	730,923	139,115	41,273	37,005	1,406,889
2009	330	160,178	322,262	283,456	76,026	291,776	71,652	23,085	15,466	519,304
2009	331	35,535	88,308	74,389	17,869	74,122	11,538	5,895	3,219	142,052

		Total Medication Cost per Antihypertensive Medication Class (in \$)								
Year	HRR	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin Angiotensin Antagonists	Combined Therapy
2009	332	48,487	116,164	89,273	25,741	110,610	23,651	5,421	4,102	181,772
2009	334	172,441	283,903	283,924	73,156	279,435	64,779	22,922	7,700	471,104
2009	335	97,772	216,342	186,877	52,859	164,105	46,383	17,996	9,425	308,924
2009	336	46,162	109,469	77,944	24,603	113,558	26,831	4,670	3,598	208,239
2009	339	390,398	920,587	720,399	230,524	738,982	197,065	26,645	41,140	1,824,949
2009	340	303,178	647,103	517,823	147,716	532,540	124,137	21,088	31,681	1,159,415
2009	341	34,124	75,195	47,363	12,532	43,636	8,972	1,371	-	75,310
2009	342	112,449	264,688	148,428	45,101	171,367	30,533	3,940	4,105	242,223
2009	343	88,703	209,389	132,558	34,760	150,331	26,614	6,135	7,771	225,950
2009	344	253,175	580,419	336,056	100,039	371,846	74,961	14,272	9,443	511,289
2009	345	22,621	58,973	40,577	10,271	36,067	7,762	1,740	-	48,411
2009	346	297,346	701,157	523,184	136,593	562,581	99,394	8,820	31,542	1,140,109
2009	347	50,248	125,706	81,028	25,680	89,213	15,354	2,539	3,408	141,289
2009	350	97,699	203,976	178,207	51,377	195,636	24,442	7,137	8,659	287,507
2009	351	150,932	336,063	263,257	75,390	230,349	51,695	16,588	6,979	427,417
2009	352	211,959	451,145	351,274	86,935	341,963	66,799	22,924	9,765	598,113
2009	354	24,240	64,880	47,018	13,798	43,161	10,165	1,827	2,864	106,871
2009	355	131,096	270,913	202,273	59,686	218,759	39,891	7,080	11,410	385,688
2009	356	599,677	1,373,195	1,090,566	232,923	1,141,886	208,507	68,309	44,672	1,918,631
2009	357	314,742	731,661	568,759	146,238	454,453	119,996	26,756	21,853	972,221
2009	358	148,295	262,279	192,780	50,761	243,497	24,030	14,619	14,337	441,271
2009	359	46,621	81,960	54,176	17,477	76,226	8,395	2,294	3,728	111,267
2009	360	79,864	194,823	137,717	40,492	171,108	31,705	2,404	11,278	321,650
2009	362	65,562	152,220	104,885	42,214	135,000	22,439	2,387	6,937	238,032
2009	363	94,531	177,930	156,458	41,479	145,822	23,985	13,207	3,369	286,762
2009	364	199,037	433,757	323,129	72,999	305,071	42,018	14,222	12,071	428,260
2009	365	153,697	410,779	341,362	68,962	265,409	60,625	19,787	19,643	899,921
2009	366	166,681	461,576	378,415	98,259	313,198	85,569	19,491	26,158	1,052,889
2009	367	89,391	218,844	185,936	51,655	152,813	45,884	10,315	10,419	560,789
2009	368	172,519	364,685	292,119	76,786	270,163	47,162	15,097	16,963	725,565
2009	369	58,793	133,727	159,297	32,796	114,586	26,604	7,732	5,775	315,059
2009	370	39,765	103,919	60,144	18,985	65,607	9,749	949	2,542	141,705
2009	371	185,969	442,552	331,351	99,750	372,644	48,275	15,530	15,627	621,631
2009	373	200,015	440,119	350,921	100,069	275,320	95,409	14,360	23,235	786,909
2009	374	109,930	206,768	189,731	59,102	149,655	37,105	12,294	7,800	386,474
2009	375	60,619	106,418	86,166	28,538	77,237	23,468	3,661	3,862	168,547


		Total Medication Cost per Antihypertensive Medication Class (in \$)								
Year	HRR	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin Angiotensin Antagonists	Combined Therapy
2009	376	129,957	237,043	166,784	56,355	155,781	41,466	7,158	9,469	404,628
2009	377	297,518	564,956	461,255	132,655	390,407	131,275	39,325	21,688	945,467
2009	379	347,430	671,668	680,217	186,631	539,472	161,251	87,866	23,864	1,460,803
2009	380	560,319	1,036,836	884,312	247,483	658,555	179,524	61,732	45,191	1,690,661
2009	382	61,034	124,275	112,312	31,900	135,223	34,938	3,626	2,357	273,639
2009	383	91,606	189,666	142,790	40,595	183,388	30,484	5,680	8,374	370,518
2009	385	165,647	384,117	296,078	70,880	309,612	80,067	18,622	16,095	602,300
2009	386	167,902	249,429	227,627	53,994	254,662	48,121	16,720	13,543	602,452
2009	388	32,034	62,974	67,282	15,575	73,448	16,389	5,602	1,725	132,588
2009	390	70,190	181,086	144,102	35,319	155,782	52,745	7,162	9,137	354,082
2009	391	677,496	1,524,243	1,259,603	308,412	1,294,862	319,921	73,725	57,389	2,718,741
2009	393	149,211	435,171	255,558	59,102	287,118	62,590	12,130	12,314	798,444
2009	394	236,738	488,041	443,539	104,647	481,114	124,942	24,207	14,401	972,439
2009	396	109,483	324,444	204,534	41,273	240,513	48,176	27,430	11,678	659,179
2009	397	749,115	1,779,021	1,471,469	300,292	1,513,854	361,379	95,687	74,756	3,220,402
2009	399	43,300	88,439	82,513	23,271	75,890	14,696	4,249	3,582	177,885
2009	400	158,215	260,177	239,763	69,011	264,687	62,195	10,676	9,111	544,044
2009	402	121,545	480,380	253,074	52,300	359,710	48,314	15,804	14,020	1,048,426
2009	406	77,274	161,766	110,259	27,911	140,285	20,642	6,346	10,651	360,472
2009	411	36,097	77,695	56,738	15,395	57,702	12,353	2,249	1,808	125,985
2009	412	386,557	866,742	573,486	142,802	610,794	147,302	39,639	36,018	1,439,411
2009	413	33,643	81,349	69,053	16,517	64,415	16,801	4,924	1,517	100,020
2009	416	135,470	291,431	220,706	64,883	248,643	55,338	8,924	10,124	517,506
2009	417	51,301	140,356	70,606	26,865	92,981	23,860	4,862	7,118	232,302
2009	418	55,853	108,773	121,549	31,656	122,640	28,789	2,895	2,909	223,029
2009	420	52,614	100,764	74,286	24,966	89,388	26,961	1,545	2,453	185,991
2009	421	32,687	62,632	34,475	12,130	45,588	7,758	754	5,726	93,319
2009	422	26,428	60,417	39,236	15,157	45,353	7,043	890	3,625	141,091
2009	423	203,692	428,251	257,957	90,767	290,740	46,954	9,235	20,079	664,714
2009	424	151,509	372,081	216,590	57,677	224,184	33,808	5,597	4,400	300,456
2009	426	162,243	507,672	321,880	56,583	352,438	67,329	13,327	18,707	724,861
2009	427	156,918	348,522	223,605	67,762	217,446	45,584	7,646	9,142	447,277
2009	428	89,136	132,509	113,941	28,644	91,738	17,435	8,170	4,022	232,191
2009	429	85,379	215,531	157,035	34,518	141,799	44,658	11,985	8,599	352,998
2009	430	177,011	410,172	353,915	81,526	305,740	89,328	34,102	15,465	695,128
2009	431	311,401	759,135	651,721	158,614	497,243	136,300	36,109	29,641	1,189,935

		Total Medication Cost per Antihypertensive Medication Class (in \$)								
Year	HRR	ACE Inhibitors	Angiotensin II Receptor Antagonists	Calcium Channel Blockers	Diuretics	Beta Blockers	Anti-Adrenergic Agents	Vasodilators	Other Renin Angiotensin Antagonists	Combined Therapy
2009	432	209,854	428,261	363,476	93,733	317,992	72,488	13,555	10,111	688,905
2009	435	81,278	202,802	146,207	36,146	148,959	24,126	5,835	6,583	308,812
2009	437	88,488	178,044	107,453	34,288	103,444	21,496	5,653	2,919	100,976
2009	438	55,089	126,132	74,348	27,173	76,763	12,402	3,993	2,263	102,986
2009	439	386,686	892,213	555,535	157,780	545,564	105,988	21,832	18,168	644,751
2009	440	256,029	544,511	362,288	117,454	327,197	67,325	8,480	11,844	531,554
2009	441	86,547	237,664	146,036	43,732	147,323	28,241	11,406	4,522	201,151
2009	442	61,183	128,175	62,649	21,337	66,734	13,291	5,059	897	76,597
2009	443	236,161	474,492	372,864	108,371	388,921	86,015	14,616	36,180	852,416
2009	444	91,179	178,654	144,327	39,489	146,546	28,044	10,692	6,305	289,358
2009	445	104,587	213,755	149,168	44,858	181,995	36,297	10,564	8,248	307,350
2009	446	36,462	61,787	46,667	16,527	60,869	9,981	1,780	1,514	82,921
2009	447	76,828	151,970	107,243	38,760	128,017	21,482	5,338	2,638	206,580
2009	448	53,867	115,346	73,258	25,729	95,623	11,246	3,038	721	88,584
2009	449	125,655	252,890	204,411	67,604	163,932	43,293	9,977	5,742	218,022
2009	450	58,055	120,548	80,536	25,834	93,880	17,998	5,602	1,867	103,331
2009	451	377,935	961,113	669,516	182,336	651,414	160,407	35,600	29,272	1,396,099
2009	452	27,653	57,658	40,437	12,954	43,745	10,389	1,842	1,119	62,578
2009	456	32,562	64,583	44,553	16,272	58,789	6,762	4,102	2,038	68,287
2009	457	47,466	86,309	48,624	19,542	54,717	10,536	1,775	1,852	129,034


Table 16. Dartmouth Atlas of Health Care Maps of Total Drug Cost by Antihypertensive Drug Class Among Medicare Parts A, B, and D Beneficiaries With Hypertension, by Hospital Referral Region, 2009




Total Drug Cost (\$) for
Angiotensin II Receptor Antagonists, 2009




Total Drug Cost (\$) for
Anti-adrenergic Agents, 2009




Total Drug Cost (\$) for Beta Blockers, 2009




Total Drug Cost (\$) for
Calcium Channel Blockers, 2009




Total Drug Cost (\$) for
Combined Products, 2009



Total Drug Cost (\$) for Diuretics, 2009



Total Drug Cost (\$) for
Other Renin-angiotensin System Antagonists, 2009



Total Drug Cost (\$) for Vasodilators, 2009

